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Cell proliferation is a fundamental biological process, and the ability of human 
cells to transition from a quiescent to proliferative state is essential for tissue 
homeostasis. Most cells in eukaryotic organisms are in a quiescent state, but on 
appropriate physiological or pathological stimuli, many types of somatic cells may exit 
quiescence, re-enter the cell cycle and begin to proliferate. The ability of cells to remain 
viable while quiescent, exit quiescence and re-enter into the cell cycle is the basis for 
varied physiological processes such as wound healing, lymphocyte activation and 
hepatocyte regeneration, but is also a hallmark of cancer. The transition of mammalian 
cells from quiescence to proliferation is accompanied by the differential expression of 
several microRNAs (miRNAs) and transcription factors. Our understanding of miRNA 
biology has significantly improved, but the miRNA regulatory networks that govern cell 
proliferation are still largely unknown. 
We characterized a miR-22 Myc network that mediates proliferation through 
regulation of the interferon response and multiple cell cycle arrest genes. We identified 
several cell cycle arrest genes that regulate the effects of the tumor suppressor p53 as 
direct targets of miR-22, and discovered that miR-22 suppresses interferon gene 
expression. We go on to show that miR-22 is activated by the transcription factor Myc as 
quiescent cells enter proliferation, and that miR-22 represses the Myc transcriptional 
repressor MXD4, mediating a feed forward loop to elevate Myc expression levels. 
To more effectively determine miRNA targets, we utilized a combination of 
RNA-induced silencing complex immunoprecipitations and gene expression profiling. 
 vii 
Using this approach for miR-191, we constructed an extensive transcriptome wide miR-
191 target set. We show that miR-191 regulates proliferation, and targets multiple proto-
oncogenes, including CDK9, NOTCH2, and RPS6KA3. 
Recent advances in determining miRNA targetomes have revealed widespread 
non-canonical miRNA-target pairing. We experimentally identified the transcriptome 
wide targets of miR-503, miR-103, and miR-494, and observed evidence of non-
canonical target pairing for these miRNAs. We went on to confirm that miR-503 requires 
pairing outside of the canonical 5’ seed region to directly target the oncogene DDHD2. 
Further bioinformatics analysis implicated miR-503 and DDHD2 in breast cancer 
tumorigenesis. 
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Chapter 1 Introduction 
1.1 CELL PROLIFERATION 
 Cell proliferation is a basic biological process, and the ability of human cells to 
transition from a quiescent to proliferative state is required for tissue homeostasis. The 
majority of cells in an adult organism primarily exist in a quiescent state that is actively 
maintained by various genetic programs (1, 2). The ability of cells to re-enter the cell 
cycle given the appropriate stimuli is vital for numerous physiological processes. 
Maintenance of proliferative potential is necessary for lymphocyte activation, hepatocyte 
regeneration, and wound healing (1-6). The transition from quiescence to proliferation of 
cells re-entering the cell cycle is exquisitely controlled by multiple check points and fail 
safe mechanisms, but is still susceptible to deregulation by disruption of the necessary 
pathways. Disruption of the actively maintained state of quiescence and sustained 
proliferative signaling are two of the basic requirements for tumorigenesis (7). 
1.1.1 The role of proliferation in cancer 
 The ability to chronically sustain proliferative signaling is arguably the most 
fundamental trait of cancer. Cell cycle deregulation is essential for tumorigenesis. Cancer 
cells possess numerous other physiological abnormalities, typically resistance to 
apoptosis, angiogenesis, and invasion and metastasis; however, cancer is often considered 
to be foremost a disease of the cell cycle (7). The pathways that control proliferation in 
normal cells are generally perturbed in cancer (7, 8). Many cell cycle regulators that 
control reentry and progression through the cell cycle are altered in cancer cells, and a 
number of cancer driver genes are direct regulators of the cell cycle (7-9). Specifically, 
the transition to G1 is deregulated in many cancers, allowing cancer cells to avoid 
entering quiescence and halting proliferation (4). 
1.1.2 Primary human dermal fibroblasts as a model for proliferation 
Primary human dermal fibroblasts are an excellent model to study the genetic 
pathways that regulate the transition from quiescence to proliferation. Primary fibroblasts 
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may be induced to enter or exit a quiescent state in response to exposure to or deprivation 
from serum containing growth factors. Fibroblast proliferation plays a central role in the 
wound healing process, and serum stimulation of fibroblasts produces a genetic program 
similar to that of wound healing (9). The wound response program is similar at the 
physiological level to cancer progression; wounding activates signaling cascades that lead 
to epithelial and fibroblast cell proliferation, matrix remodeling, cell migration, and 
angiogenesis (9). At the genetic level, many of the genes differentially expressed in 
fibroblasts following serum stimulation are also differentially expressed in tumor cells, 
associated fibroblasts, or both, and include a number of key cell cycle regulators (10). In 
addition, the expression profiles of proliferating fibroblasts are good predictors of cancer 
progression (7, 8, 10). Multiple protein coding genes and miRNAs are differentially 
expressed between proliferating and quiescent fibroblasts (7-9, 11). 
1.2 MIRNAS 
One of the main classes of regulators that have been shown to mediate cell 
proliferation and tumorigenesis are miRNAs (4, 12). miRNAs are short, noncoding RNAs 
that post-transcriptionally regulate gene expression. They are ubiquitous regulators of 
multiple cellular pathways and biological processes such as metabolism, immune 
defense, development, differentiation, proliferation, and apoptosis (9, 13, 14). miRNAs 
are predicted to regulate ~50% of all human protein coding genes (14). miRNAs have 
been shown to be involved in numerous pathologies, such as cardiovascular disease, viral 
diseases, and cancer development (15-17). There are currently over 1,800 human 
miRNAs reported in the miRNA database miRBase (18). miRNAs are hypothesized to 
function by subtly regulating the expression of numerous targets; although the changes in 
expression for each individual target are generally small, the coordinated regulation of 
multiple targets is thought to have strong phenotypic effects. 
1.2.1 Biogenesis 
In the standard miRNA biogenesis pathway, long primary miRNA (pri-miRNA) 
transcripts are typically produced by RNA polymerase II, although some are products of 
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RNA polymerase III (19). Roughly one third of known miRNAs are located in introns of 
protein coding genes and are co-transcribed with the host gene (19). Primary transcripts 
contain an ~60-90 nucleotide hairpin structure that is the pre-miRNA (20). The pre-
miRNA is released from the pri-miRNA in the nucleus by cleavage catalyzed by the 
RNase III endonuclease Drosha (20). The pre-miRNA is exported from the nuclease by 
Exportin 5, and further cleaved by the RNase III endonuclease Dicer to produce an ~22 
base pair RNA duplex composed of the eventual mature miRNA paired to the miRNA* 
strand (20). One of the two strands of the RNA duplex is loaded into the Argonaute-2 
(Ago2) protein, a core component of the RNA-induced silencing complex (RISC) (19). 
There are a few miRNAs that are produced by alternative pathways that typically replace 
one or more of the standard precursor processing steps (21). 
1.2.2 Mode of action 
miRNAs are the targeting component of RISC, and guide binding of RISC to 
target transcripts by nucleotide pairing. Only one strand of the mature miRNA duplex is 
loaded into RISC, and is selected based on thermodynamic asymmetry of the duplex, 
with the strand with lower stability at the 5’ end being incorporated into RISC (22). 
miRNAs direct target pairing of transcripts by pairing to sites of imperfect 
complementarity. The exact mechanism of miRNA target selection remains unclear; 
however, a set of standard rules have been experimentally established: (1) miRNA-target 
interactions are primarily mediated by the “seed” region, a continuous 6 to 8 nucleotide 
sequence at the 5’ end of the miRNA that forms Watson-Crick pairing with the target; (2) 
regulation of gene expression is predominantly mediated through pairing to the 3’ UTR 
of the target mRNA, and not the 5’UTR or CDS; and (3) target site context matters, 
efficacy greatly increases for sites located nearer the ends of 3’ UTRs and in unstructured 
regions with greater site accessibility (23, 24). Perfect pairing of the miRNA to the target 
results in target cleavage, although this is rarely observed in mammals (23). Imperfect 
pairing, including standard seed pairing, accounts for the vast majority of miRNA-target 
interactions, and results in translational repression and decreased transcript stability (25). 
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1.2.3 Alternative modes of target pairing 
Transcriptome wide gene expression analysis following miRNA perturbation 
combined with sequence conservation analysis has shown that efficacious miRNA-target 
pairing is mediated through perfect pairing of the seed region (23, 24, 26). More recently 
methodologies to profile transcriptome wide RISC occupancy have revealed extensive 
RISC binding to transcripts with imperfect or nonexistent seed matches (27-30). This 
non-canonical miRNA target pairing has been observed to occur in up to 60% of miRNA-
target pairs (27). However, mediation of gene expression by non-canonical target pairing 
is modest at most, and observed to have no significant effect on gene expression in 
multiple studies (24, 29, 30). This discrepancy may be due to differences in miRNA 
target identification methods, reliance on target site conservation, and dependence on 
seed presence. 
1.2.4 miRNAs in tumorigenesis 
Multiple miRNAs may function as either tumor suppressors or oncogenes. 
miRNAs are located in 50% of all fragile regions or cancer associated sites, with 
oncogenic miRNAs mainly located in amplified regions and tumor suppressor miRNAs 
generally located in deleted regions (19, 31). Disruption of the miRNA biogenesis 
pathway typically results in tumorigenesis (32). miRNAs have been shown to regulate the 
function of many of the major processes involved in tumorigenesis, including 
proliferation, migration, invasion, and angiogenesis (16, 19). The first miRNAs shown to 
be involved in cancer were those composing the miR-15a/miR-16-1 cluster, which is 
frequently deleted in chronic lymphocytic leukemia, and targets several promoters of cell 
cycle progression, including CDK6, CARD10, and CDC27 (33). miR-21 is the most 
commonly reported miRNA to function as an oncogene, and does so in multiple cancer 
types including glioblastoma, hepatocellular carcinoma, prostate cancer, and breast 
cancer, and depending on context targets multiple tumor suppressors including p53 and 
PTEN (34-36).  
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Chapter 2 A Myc–microRNA network promotes exit from quiescence 
by suppressing the interferon response and cell-cycle arrest genes 
2.1 ABSTRACT 
The transition of mammalian cells from quiescence to proliferation is 
accompanied by the differential expression of several miRNAs and transcription factors. 
However, the interplay between transcription factors and miRNAs in modulating gene 
regulatory networks involved in human cell proliferation is largely unknown. Here we 
show that the miRNA miR-22 promotes proliferation in primary human cells, and 
through a combination of RISC immunoprecipitation and reporter assays, we identified 
multiple novel targets of miR-22, including several cell-cycle arrest genes that mediate 
the effects of the tumor-suppressor p53. In addition, we found that miR-22 suppresses 
interferon gene expression by directly targeting HMGB1 and IRF5, preventing activation 
of IRF3 and NF-κB, which are activators of interferon genes. The expression of 
interferon genes is elevated in quiescent cells and their expression is inhibitory for cell 
proliferation. In addition, we find that miR-22 is activated by the transcription factor Myc 
when quiescent cells enter proliferation, and that miR-22 inhibits the Myc transcriptional 
repressor MXD4, mediating a feed-forward loop to elevate Myc expression levels. Our 
results implicate miR-22 in down regulating the anti-proliferative p53 and interferon 
pathways and reveal a new transcription factor-miRNA network that regulates the 
transition of primary human cells from quiescence to proliferation. 
2.2 INTRODUCTION 
miRNAs have emerged as important regulators of cell proliferation driving 
tumorigenesis, and several studies have functionally linked miRNAs and transcription 
factors in regulatory networks that govern cell proliferation and cancer (37, 38). The 
miRNA miR-22 has been reported to act as both a proto-oncogene in various cancer cell 
lines and a tumor suppressor in other cancer cell lines, as well as being involved in panic 
disorder, hypoxia signaling, differentiation, and cardiomyocyte hypertrophy (21-24). 
miR-22 was shown to promote cell proliferation, invasion, and survival in multiple 
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cancer cell types by regulating PTEN (39-41). However, miR-22 has also been 
demonstrated to repress proliferation by inhibiting the binding partners, MAX and 
MCYBP, of the oncogene Myc (42-44). In addition, miR-22 was shown to inhibit cancer 
progression by inducing cellular senescence (45), and to repress cell migration and 
invasion in ovarian cancer (46). miR-22 has also been linked to the p53 regulatory 
network, is a direct target of the tumor suppressor p53, and mediates p53 induced cell 
cycle arrest and apoptosis in colon cancer (43). Despite the broad involvement of miR-22 
in tumorigenesis in various cancers, the activity of miR-22 in primary cells has not been 
explored. 
In this study we investigate the regulation of cell proliferation in primary cells by 
miR-22, and identify a new regulatory network mediating the transition of primary cells 
from quiescence to proliferation. This network involves the activation by the oncogene 
Myc of miR-22, which in turn suppresses the interferon and cell cycle arrest pathways 
active in quiescent cells, thus facilitating their re-entry into the cell cycle. Our data 
reveals novel cross-talk between the p53 and Myc regulatory networks that is mediated 
by mir-22. 
2.3 MATERIALS AND METHODS 
2.3.1 Normal cell culture conditions 
HeLa cells and human foreskin fibroblasts (ATCC CRL #2091) were maintained 
in DMEM (Dulbecco’s Modified Eagle’s Medium) supplemented with 10% FBS (Fetal 
Bovine Serum) at 37°C under 5% CO2. Fibroblasts were made quiescent by first growing 
them under normal conditions until 40% confluent, then replacing medium with DMEM 
supplemented with 0.1% FBS and growing them for a further 48 hours. 
2.3.2 Fibroblast serum stimulation 
Fibroblast cell cultures were grown under normal cell culture conditions until 
40% confluent. Medium was removed and cell cultures were washed 3 times with PBS 
(Phosphate Buffered Saline). Replacement medium was DMEM supplemented with 0.1% 
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FBS and 100 units penicillin-streptomycin. Cell cultures were grown at 37°C for 48 
hours. Cell cultures were washed 1x with PBS. Reference cell cultures were harvested 
following total RNA Isolation. Replacement medium was DMEM supplemented with 
10% FBS and 100 units penicillin-streptomycin. Separate cell cultures were allowed to 
proliferate under serum-rich conditions for time-points of 5, 10, 20, 30, 60, and 180 
minutes. At the end of each of these time points, cell cultures were harvested for total 
RNA isolation using the TRIzol reagent (Invitrogen) according to manufacturer’s 
protocol. 
2.3.3 Myc overexpression  
HeLa cell cultures were grown under normal cell culture conditions. 6-well plates 
were seeded with 1.5 x 105 cells/well. Cell cultures were allowed to grow for 24 hours. 
Cell cultures were lipotransfected with Invitrogen Lipofectamine 2000 according to the 
manufacturer’s protocol (for DNA plasmid transfection). Myc overexpression plasmid 
was purchased from Open Biosystems (MHS1010-57504, Human MGC Verified FL 
cDNA, CloneID = 298544). GFP co-transfection plasmid was purchased from Clontech 
(Vector=pEGFP-N1, Accession=U55762). Cell cultures were grown under normal cell 
culture conditions for 48 hours and then harvested for total RNA. 
2.3.4 Myc knockdown 
Myc-specific siRNA and negative control siRNA were purchased from 
Dharmacon. HeLa cell cultures were grown under normal cell culture conditions. 6-well 
plates were seeded with 1.5 x 105 cells/well. Cell cultures were allowed to grow for 24 
hours. Cell cultures were lipotransfected with Invitrogen Lipofectamine 2000 according 
to the manufacturer’s protocol (for siRNA transfection). Cell cultures were grown under 
normal cell culture conditions for 48 hours and then harvested for total RNA. For serum 
stimulation experiments under conditions of Myc knockdown, fibroblasts were 
transfected with siRNAs against Myc or negative control siRNA and cells were starved 
into quiescence. Quiescent fibroblasts were then serum-stimulated for the indicated time 
points and miR-22 expression was assayed by quantitative qRT-PCR (qRT-PCR). 
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2.3.5 miRNA enrichment, labeling, and microarrays 
Ambion FlashPAGE Fractionator System, Pre-cast Gels, Buffer Kit, and Clean-
Up Kit were used according to the manufacturer’s protocol. Invitrogen ULYSIS 546 
Nucleic Acid Labeling Kit was used for the typical Cy3 sample. Invitrogen ULYSIS 647 
Nucleic Acid Labeling Kit was used for the typical Cy5 sample. The kits were used 
according to the manufacturer’s protocol. Ambion FlashPAGE Clean-Up Kits were used 
for removal of unincorporated dye according to the manufacturer’s protocol. Labeled 
small RNAs were hybridized to dual channel miRNA microarrays, quantitated and 
normalized. The microarrays were printed in house with the v1 Ambion array probe set 
that includes 281 human miRNAs registered in miRBase. 
2.3.6 Real time miRNA PCR 
Quantitative real-time PCR was performed for miR-22 using Applied Biosystems 
TaqMan miRNA Assays according to the manufacturer’s protocol.  
2.3.7 Quantitative Reverse-Transcription PCR for interferon stimulated genes 
RNA from quiescent and proliferating fibroblasts was extracted with the TRIzol 
reagent (Invitrogen) and reverse transcribed using random hexamers and the Superscript 
II system from Invitrogen. PCR was performed using the SYBR GREEN PCR Master 
Mix from Applied Biosystems. The target gene mRNA expression was normalized to the 
expression of GAPDH and relative mRNA fold changes were calculated by the ΔΔCt 
method. 
2.3.8 Myc binding site detection and motif analysis 
Chromatin immunoprecipitation for Myc was performed as previously described 
(47). ChIP-enriched DNA was sequenced by Illumina sequencing technology. Short reads 
from the ends of DNA fragments were mapped back to the genome using Maq. 
Conservation was quantified according to the mammalian conservation track from 
UCSC, specifically, the 17-species conservation and alignment track (phastCons17way). 
Conservation was evaluated for each locus through local installation of a portion of 
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UCSC’s Genome Browser and command-line execution of UCSC toolsets (hgWiggle) 
that retrieved conservation metrics for a specified genomic range. The mean conservation 
of conserved motifs was 90% (standard deviation is 6.7%) while the mean conservation 
of the non-conserved motifs was 0.6% (standard deviation is 0.3%). The presence of 
proximal CpG islands was evaluated using the CpG enrichment track (cpgIslandExt). 
Conserved binding motif coordinates for Myc across the genome were obtained from 
UCSC’s catalog of conserved binding sites for all mammalian transcription factors 
[TFBS Conserved]. Motif search was performed within 20 kb upstream of the miRNA 
start sites. For the ChIP-PCR assay, fibroblasts were starved into quiescence and then 
serum stimulated to proliferate. Cells were harvested 3 hours after stimulation and ChIP 
was performed as described above. Myc binding was confirmed using quantitative PCR 
performed using the SYBR GREEN PCR Master Mix from Applied Biosystems. Fold 
enrichment was calculated with respect to the negative control by the ΔΔCt method.  
2.3.9 RNA oligos, transfections, and microarray analysis 
miR-22 guide and anti-guide mature sequences were obtained from miRBase 
(http://microRNA.sanger.ac.uk/sequences/) while sequences for siRNA against GFP 
(control siRNA) were obtained from (48). The corresponding RNA oligos were ordered 
from Invitrogen or IDT and annealed in RNA annealing buffer (20 mM HEPES, pH 7.3, 
50 mM KCl, 2 mM MgCl2). Both the miR-22 and control siRNA oligos contain the same 
chemical modifications of 5’ phosphate and 3’ OH. The RNA duplexes were transfected 
at a final concentration of 100 nM using Lipofectamine 2000 according to the 
manufacturer’s instructions. The miR-22 inhibitor and control were a miRCURY Locked 
Nucleic Acid (LNA) miRNA Inhibitor and Negative Control Inhibitor obtained from 
Exiqon and transfected at a final concentration of 10 nM using Lipofectamine 2000. Poly 
I:C was obtained from Sigma Aldrich and co-transfected at a final concentration of 200 
ng/ml with miR-22 or control siRNA duplexes as described above. RNA from transfected 
cells was extracted using the Trizol reagent (Invitrogen), amplified and hybridized to in-
house cDNA expression microarrays as previously described (49). Functional analysis for 
repressed genes was performed using the freely available online software DAVID (50). 
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2.3.10 Flow cytometry 
Fibroblasts were seeded at 50,000 cells per well in 6 well plates. Cells were 
cultured in DMEM supplemented with 10% FBS. Cells were allowed to grow 24 hours, 
and then media was replaced with low serum DMEM 0.1% FBS. 8 hours after 
replacement with DMEM 0.1% FBS, cells were transiently transfected with miR-22 or 
control siRNA duplexes (100 nM final concentration). 28 hours after transfection, cells 
were trypsinized, washed with PBS, and fixed for 24 hours in 70% ethanol at -20°C. 
After ethanol fixation, cells were washed with Stain Buffer (BD Pharmingen), incubated 
30 minutes with FITC Mouse Anti-Human Ki67 antibody (BD Pharmingen), washed, and 
resuspended in 500 µl Stain Buffer with Propidium Iodide Staining Solution (5 µg/ml) 
(BD Pharmingen). Flow cytometry analysis for Ki67 was done using a FACsCalibur flow 
cytometer and 10,000 events above threshold levels were counted for each sample (BD 
Biosciences). Data analysis was done using FlowJo. 
2.3.11 Luciferase assays 
Entire 3' UTRs, if possible, or at least 0.8 to 1.2 kb around the predicted miR-22 
site in a 3’ UTR was cloned into a Renilla vector under a CMV promoter. For CARF, we 
included the last exon in addition to the 3’UTR for the luciferase assays. miRNA seed 
site mutants were made by mutating 3 base pairs in the 6-mer seed sequence using 
Agilent’s QuikChange MultiSite-Directed Mutagenesis Kit. Another vector containing 
the Firefly luciferase under a CMV promoter was used as a normalization control. 
HEK293 cells were plated in 24-well plates at 105 cells/well and Renilla and Firefly 
vectors were co-transfected at 25 ng each along with 100 nM final concentration of miR-
22. Control siRNA was used as a negative control. Cells were harvested 24 hours post-
transfection and luciferase activity was measured using the Promega Dual Luciferase kit 
according to manufacturer’s instructions. Fold suppression was calculated as the ratio of 
Renilla to Firefly values for miR-22 normalized by the mean of the Renilla to Firefly 
ratios for the control siRNA. For the NF-κB reporter assays, HEK293 cells were plated in 
24-well plates at 1 x 106 cells/well. 24 hours after plating, cells were transfected with 100 
ng/well of NF- κB reporter plasmid (SABiosciences), and co-transfected with poly I:C 
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and miR-22 or the control siRNA. Cells were harvested 16 hours post-transfection and 
luciferase activity was measured as described above. For Fig. 5E and F, we performed 
luciferase assays using a pGL3 promoter plasmid (Promega) as previously described (51). 
Around 550 bp of PCR-amplified insert from each of 4 putative Myc binding sites was 
cloned into the vector. 
2.3.12 Western blots 
For westerns of phosphorylated and native IRF3, HeLa cells were seeded in 6-
well plates at 8 x 104 cells/well and co-transfected with 200 ng/ml poly I:C and miR-22 
or the control siRNA. 12 hours after transfection, cells were harvested for protein 
analysis. Cell lysates were separated on 10% SDS-PAGE gels and proteins were 
transferred onto PVDF membranes. Membranes were blocked with 5% milk in TBST (25 
mM Tris pH 8.0, 150 mM NaCl, 0.05% Tween-20) and probed with corresponding 
primary antibodies against specific proteins (phosphorylated and native IRF3: Cell 
Signaling Technology). HRP-conjugated secondary antibodies (Santa Cruz 
Biotechnology) were used to detect primary antibodies, and proteins were visualized by 
chemiluminescence. 
For Westerns of putative miR-22 targets, primary human fibroblasts were seeded 
in 6-well plates at 2 x 104 cells/well in DMEM supplemented with 10% FBS. 24 hours 
after plating, media was replaced with low serum DMEM 0.1% FBS. The media for 
proliferating samples was replaced with more DMEM 10% FBS. 48 hours after serum 
starvation, miR-22 or control siRNA was transfected at a 100 nM concentration, and 
proliferating and quiescent samples were lysed. Transfected cells were lysed at 12 hr, 24 
hr, 48 hr, or 72 hr post transfection. Cell lysates were separated on 4-20% gradient SDS-
PAGE gels (Biorad) and proteins were transferred onto PVDF membranes. Membranes 
were blocked with 5% milk in TBST and probed with corresponding primary antibodies 
against specific proteins (HMGB1: Cell Signaling Technology, IRF5: Abcam ab33478, 
REDD1: Abcam ab106356, TP53INP1: Abcam ab9755, p21: Abcam ab7960, CARF: 
ab88322, MXD4: Santa Cruz Biotechnology sc-771, MYC: Santa Cruz Biotechnology 
sc-764X). Actin was used as a loading control (Actin: Santa Cruz Biotechnology sc-
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10731). HRP-conjugated secondary antibodies (Santa Cruz Biotechnology sc-2004 and 
sc-2005) were used to detect primary antibodies, and proteins were visualized by 
chemiluminescence. Westerns shown are for the time point that showed the strongest 
repression. 
2.3.13 Ago2 immunoprecipitation 
We adapted the protocol developed by Hendrickson et. al. (52) for 
immunoprecipitating Ago2-mRNA complexes. Briefly, HeLa cells were grown in 10 cm2 
tissue culture plates and transfected with either miR-22 mature duplexes at a final 
concentration of 100 nM or mock transfected. After 24 hours, 0.5 ml of lysis buffer was 
added drop-wise onto the cell monolayer followed by incubation at 4°C for 30 minutes. 
Cell lysate was collected by scrapping and cleared by centrifugation at 14,000 rpm at 
4°C. Cleared lysate was then incubated with 50 µl of protein-G beads (Roche) for 3 hours 
at 4°C (pre-clearing). Before pre-clearing, 50 µl of the cleared lysate was removed for 
total RNA estimation. Pre-cleared lysate was incubated with 15 µg of Ago2 antibody 
(ab57113, Abcam) and incubated at 4°C overnight. The next day, 50 µl of protein-G 
beads were added to the lysate and incubated for 4 hours at 4°C. Beads were washed 8 
times with lysis buffer and Ago2-RNA complexes were extracted by adding 1 ml Trizol 
reagent (Invitrogen) directly to the beads. RNA extraction was carried out as per the 
manufacturers instructions. 
2.3.14 Cell counting assays 
For miRNA overexpression experiments, fibroblasts were seeded at 20,000 cells 
per well in 6 well plates. Cells were cultured in DMEM supplemented with 10% FBS. 
Cells were allowed to grow 24 hours, and then media was replaced with low serum 
DMEM 0.1% FBS. 24 hours after replacement with DMEM 0.1% FBS, cells were 
transiently transfected with miR-22 or siGFP duplexes (100 nM final concentration). 0, 
24, 48, 72, and 96, hours after transfection, cells were trypsinized, and counted in a 
hemacytometer. 5 fields were averaged for each biological replicate. For miRNA 
inhibition experiments, fibroblasts were seeded at 20,000 cells per well in 6 well plates. 
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Cells were cultured in DMEM supplemented with 10% FBS. Cells were allowed to grow 
24 hours, and then transiently transfected with miR-22 miRCURY Locked Nucleic Acid 
(LNA) miRNA Inhibitor and Negative Control Inhibitor obtained from Exiqon (10 nM 
final concentration). 0, 24, 48, 72, and 96 hours after transfection, cells were trypsinized, 
and counted in a hemacytometer. 5 fields were averaged for each biological replicate. 
2.3.15 Statistical analysis 
Statistical significance was estimated using a one-sided Student’s t-test. 
2.4 RESULTS 
2.4.1 miR-22 is induced during the transition from quiescence to proliferation and 
promotes proliferation 
Microarray expression profiling identified multiple miRNAs that are differentially 
expressed in primary human fibroblasts induced to transition from quiescence to 
proliferation by serum stimulation (Figure 2.1A). We focused on miR-22 because it was 
one of the miRNAs most strongly and consistently induced by serum stimulation, and 
bioinformatic analysis suggested that it could be transcriptionally regulated by 
immediate-early transcription factors (not shown). qRT-PCR for miR-22 expression after 
serum stimulation of fibroblasts in an independent biological replicate experiment 
confirmed its induction (Figure 2.1B). 
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Figure 2.1 miR-22 is induced during the transition from quiescence to proliferation. 
(A) Heat map showing the response of miRNAs to serum stimulation of quiescent 
primary human fibroblasts measured using microarrays. Ratios displayed represent the 
average activation across all measured time-points after serum stimulation (5, 10, 20, 30, 
60, and 180 minutes). miRNAs shown were activated or repressed greater than 1.5 fold 
on average in serum stimulated compared to serum starved cells. (B) Independent qRT-
PCR verification of miR-22 expression during the transition from quiescence to 
proliferation. The Y-axis indicates expression of miR-22 after serum stimulation relative 
to quiescence, at each of the indicated time points on the X-axis. Data shown is for a 
representative experiment measured in quadruplicate (mean ± s.d.). 
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Since miR-22 was activated during the transition of primary human cells from 
quiescence to proliferation, we hypothesized that miR-22 regulates proliferation in 
primary human cells. To test this hypothesis, we transiently overexpressed miR-22 by 
transfecting the mature form of the miR-22 duplex RNA into quiescent fibroblasts and 
assayed cell growth. Compared to the control, miR-22 transfected cells showed increased 
growth by cell counting assay (Figure 2.2A). Conversely, proliferating cells in which we 
introduced a stable antisense inhibitor of miR-22 showed decreased cell growth (Figure 
2.2B). To further explore the effect of miR-22 on cell growth we assayed the expression 
of the proliferation marker Ki67 (53, 54). We transfected miR-22 into quiescent 
fibroblasts and counted cells expressing Ki67 protein using flow cytometry. miR-22 
transfection significantly increased the percentage of Ki67 positive cells compared to 
control, indicating that miR-22 activates proliferation (Figure 2.2C). We confirmed this 
result by performing a biologically independent experiment where we transfected miR-22 
into both quiescent fibroblasts and proliferating fibroblasts, and measured Ki67 
expression by qRT-PCR. Compared to the control, miR-22 transfected cells showed 
elevated levels of Ki67 in both quiescent fibroblasts and proliferating fibroblasts (Figure 
2.2D & 2.3). In addition, inhibition of miR-22 decreased levels of Ki67 compared to the 
control in cells exiting quiescence (Figure 2.2E). 
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Figure 2.2 miR-22 activates proliferation. 
(A) Cell growth assay following miR22 overexpression. Average cell number following 
miR-22 or control siRNA transfection is shown for each time point indicated. Error bars 
denote ± s.d., n=3. (B) Cell growth assay following miR-22 inhibition. Average cell 
number following transfection of a Locked Nucleic Acid (LNA) targeting miR-22 or a 
LNA negative control is shown for each time point indicated. Error bars denote ± s.d., 
n=3. (C) Flow cytometry analysis for proliferation marker Ki67 of miR-22 transfected 
quiescent fibroblasts. miR-22 transfected fibroblasts showed a larger population of cells 
expressing Ki67 compared to control siRNA transfected fibroblasts. The Y-axis shows 
the percentage of cells expressing Ki67. Bars are the mean percentage of cells expressing 
Ki67 and error bars denote the mean ± s.d, n=4. (D) qRT-PCR data for Ki67 expression 
in quiescent fibroblasts transfected with miR-22 duplexes compared to control siRNA. 
miR-22 transfected fibroblasts show elevated levels of Ki67 expression as compared to 
control at the indicated time points. Ki67 expression was normalized using GAPDH 
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Fig 2.2 continued. 
mRNA levels and fold changes were normalized with respect to the control transfection. 
(E) Inhibition of miR-22 decreases proliferation as measured by Ki67 expression. 
Quiescent fibroblasts were transfected with a LNA miR-22 inhibitor or LNA control. 24 
hours post transfection, cells were serum stimulated to proliferate for 18 or 24 hours prior 
to harvesting for qRT-PCR. Y-axis indicates relative Ki67 expression levels compared to 
quiescent cells. Bars indicate the normalized mean expression, and error bars denote ± 
s.d, n=3. Control panel depicts Ki67 expression in normally proliferating fibroblasts and 
serum starved quiescent fibroblasts. GAPDH was used as a control for normalizing input 
RNA levels. For A, B, C, and E, P-values were estimated by Student’s t-test. *, P<0.05 
 
 
Figure 2.3 miR-22 elevates levels of Ki67 in proliferating fibroblasts. 
miR-22 or control siGFP was transfected into normally growing fibroblasts, and cells 
expressing Ki67 above threshold levels were quantified by flow cytometry. The column 
graph shows Ki67 expression levels relative to the control, which was set to a value of 
1.0. Bars indicate the mean, and error bars denote ± s.d., n=3. P-values were estimated by 
Student’s t-test. *, P<0.05. 
2.4.2 Identifying miR-22 targets by microarrays 
To identify the downstream targets of miR-22 in proliferating fibroblasts, we 
overexpressed miR-22 by transfecting miR-22 duplexes and then analyzed gene 
expression using microarrays, relying on the fact that miRNAs frequently cause down 
regulation of their mRNA targets (15, 55). In order to investigate whether this approach 
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was able to identify miR-22 targets, we analyzed the 3' UTRs of genes that were down 
regulated following miR-22 transfection for enrichment of the miR-22 seed match 
sequence. We also performed the same experiment and analysis in HeLa cells. In both 
cell lines, 6-mer matches to nucleotides 2-7, the miR-22 seed region, were significantly 
enriched in genes repressed when miR-22 was overexpressed (P < 10-8 assuming a 
binomial model, Figure 2.4A & B). Thus, genes whose mRNAs were down regulated in 
response to high levels of miR-22 contained a significant proportion of direct targets of 
miR-22. 
In addition to conducting gene expression profiling following miR-22 
overexpression in proliferating cells, we also transfected miR-22 duplexes into fibroblasts 
that were rendered quiescent by serum deprivation, and analyzed the resulting gene 
expression changes and corresponding seed enrichment as described above. Although 
there was a significant enrichment of seed matches to the 5' end of miR-22 in the 3' UTRs 
of the repressed genes (P < 10-4 assuming a binomial model, Figure 2.4C), the magnitude 
of this enrichment was much lower than that observed for genes that were repressed by 
miR-22 during proliferation, suggesting that many mRNAs down regulated by miR-22 in 
quiescent cells may be indirect targets. 
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Figure 2.4 Seed match enrichment. 
Seed match enrichment among miR-22 targets identified by expression profiling in (A) 
proliferating fibroblasts, (B) HeLa cells, and (C) quiescent fibroblasts. Left panels 
indicate enrichment and right panels indicate significance of enrichment for each cell 
type. Gene expression was assayed using cDNA microarrays after miR-22 transfection. 
Genes were ranked in descending order in cumulative sets of 50 from most strongly 
repressed to least repressed, and miR-22 seed match enrichment in the 3' UTR of genes in 
each set was calculated. The vertical axis shows cumulative gene sets from 50 most 
strongly repressed, to 250 most strongly repressed. Enrichment was calculated for each 
consecutive 6-mer along the miRNA, with values displayed in yellow indicating 
enrichment and blue indicating depletion. Background frequencies for each seed were 
estimated from the 3' UTRs of all genes represented on the array. P-values were 
calculated as described in the text assuming a binomial model. The log10 of the P-value is 
plotted as indicated by the pink color scale. Each value on the horizontal axis indicates 
the start position of a 6-mer from the 5' end of the miRNA. 6-mers starting at positions 2-
4 were significantly enriched over background. 
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2.4.3 miR-22 inhibits genes involved in cell-cycle arrest 
miR-22 overexpression repressed several cell cycle related genes, suggesting 
miR-22 may regulate proliferation through repression of cell cycle arrest genes. From the 
miR-22 overexpression and gene expression profiling experiments we selected genes for 
further analysis that were cell cycle related, repressed by miR-22 overexpression, and 
contained miR-22 target sites. Of these genes, TP53INP1, REDD1 (also known as 
DDIT4) and p21 (also known as CDKN1A) are transcriptionally activated by the tumor 
suppressor p53 (56-58), while CARF (also known as CDKN2AIP) enhances p53 function 
and induces premature senescence in primary fibroblasts (59). TP53INP1, p21 and CARF 
have a functional role in inducing cell-cycle arrest (58-60) while REDD1 is a DNA-
damage inducible protein involved in apoptosis (57). TargetScan and RNA22 predicted 
REDD1, TP53INP1 and p21 as miR-22 targets. Interestingly, CARF did not show miR-
22 seed sequences in its 3' UTR but showed multiple seed matches in its last exon. 
To determine whether these genes were direct targets of miR-22, we used a 
strategy based on Ago2 immunoprecipitations (IPs) (Figure 2.5) (52, 61). Ago2 is an 
essential component of the RNA-induced silencing complex (RISC) that is directed to 
target mRNAs by the miRNA guide strand (23). Hence, changes in Ago2 occupancy on a 
mRNA that occur in a miR-22 dependent manner can serve to identify direct targets. We 
measured Ago2 occupancy of candidate target mRNAs by immunoprecipitating Ago2-
mRNA complexes and quantifying enrichment of the purified transcripts by qRT-PCR. 
We performed parallel Ago2 IPs in HeLa cells that were transfected with miR-22 mature 
duplexes as well as in mock transfected cells. HeLa cells were used for the Ago2 IPs due 
to their greater RNA content and smaller size than human fibroblasts, resulting in much 
higher mRNA yield per Ago2 IP. Transcripts that showed an increase in Ago2 occupancy 
in the miR-22 transfected samples as compared to mock transfections were expected to 
be direct miR-22 targets. We measured Ago2 occupancy by qRT-PCR using GAPDH as 
a control. Transcript abundance in the IPs was normalized to that in an aliquot of the total 
RNA prior to Ago2 IP. 
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Figure 2.5 Argonaute 2 immunoprecipitation (Ago2 IP). 
Ago2 forms a complex with the miRNA and the target mRNA. This complex is 
immunoprecipitated and the mRNA levels are quantified with qRT-PCR.  
 
Ago2 IP confirmed REDD1, TP53INP1, p21 and CARF as direct targets of miR-
22, as all four genes specifically showed increased Ago2 occupancy in a miR-22 
dependent manner (Figure 2.6A), whereas other cell-cycle regulatory genes did not (data 
not shown). We confirmed that all four genes were directly down regulated by miR-22 
using a 3' UTR luciferase reporter assay, and that miR-22 mediated repression of the 3’ 
UTRs in the assay was dependent on the predicted miR-22 target sites in the 3’UTRs 
(Figure 2.6B). 
The transcripts of three of these four genes (TP53INP1, p21 and REDD1) were up 
regulated as fibroblasts entered quiescence (Figure 2.6C). We therefore assayed whether 
ectopic miR-22 could inhibit these genes in quiescent cells. We transfected miR-22 into 
quiescent fibroblasts and assayed the changes of these three genes transcript levels by 
qRT-PCR and changes in protein expression by western blot. miR-22 suppressed the 
transcript and protein expression of the three genes in quiescent cells (Figure 2.6D & 
2.6E). Protein levels of CARF were also down regulated in quiescent cells transfected 
with miR-22 compared to control (Figure 2.6E). 
 
genes are activated as fibroblasts enter quiescence (51). To
confirm that interferon response genes were activated
under quiescence, we measured relative mRNA expression
levels of IFNB1, a key marker and inducer of the type I
interferon response, as well as several ISGs in proliferating
and quiescent fibroblasts. All of the interferon genes that
we tested were expressed at higher levels in quiescent cells
(Figure 4D). The interferon response is potently anti-pro-
liferative (52), and the elevated expression of interferon
genes could potentially be part of intrinsic mechanisms
maintaining cellular quiescence.
To verify that an active interferon response would be
detrimental to proliferation, we artificially activated the
interferon pathway by transfecting poly I:C into quiescent
fibroblasts, then stimulated them with serum to induce
proliferation and assayed expression of proliferation
marker Ki67. Quiescent fibroblasts that were not treated
with poly I:C showed efficient exit from quiescence into a
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Figure 2. miR-22 targets genes mediating cell-cycle arrest. (A) Ago2 IP. Ago2 forms a complex with the miRNA and the target mRNA. This
complex is immunoprecipitated and the mRNA levels are quantified with qRT-PCR. (B) Ago2 IPs identify genes mediating cell-cycle arrest and
apoptosis as direct targets of miR-22. REDD1, TP53INP1, p21 and CARF transcripts show significantly higher Ago2 occupancy in miR-22–
transfected HeLa cells compared with mock-transfected cells. Ago2 occupancy of the target genes transcripts was measured using qRT-PCR as
described in the text. The Y-axis shows fold change in mRNA levels from Ago2 IP–isolated RNA normalized to input RNA, which served as the
control. (C) Luciferase assays show that miR-22 directly targets the 30UTRs of the genes indicated on the X-axis. IKKg and Empty are negative
controls. IKKg was not repressed by miR-22 and Empty is the luciferase vector with no UTR. The Y-axis shows relative luciferase units from
miR-22-transfected cells normalized to control siRNA transfection. For the mutant 30UTRs, 3 bp in each 6-mer miR-22 target site in the 30UTRs
were mutated. (D) qRT-PCR results for REDD1, TP53INP1, p21 and CARF transcripts show increased expression in quiescent fibroblasts relative
to proliferating fibroblasts. Y-axis indicates fold enrichment in quiescent versus proliferating fibroblasts. (E) qRT-PCR shows miR-22 suppresses
TP53INP1, REDD1 and p21 transcript levels in quiescent fibroblasts. Fold changes are denoted on the Y-axis relative to the control siRNA
transfection. (F) REDD1, TP53INP1, p21 and CARF protein expression in fibroblasts was downregulated by transfection with miR-22 compared
with control siRNA transfection. For B, D and E, GAPDH was used as a control for normalizing input RNA levels. For B, C, D and E, bars
indicate the mean, and error bars denote ±SD, n=3. P-values were estimated by Student’s t-test. *P< 0.05.
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Figure 2.6 miR-22 targets genes mediating cell-cycle arrest. 
(A) Ago2 immunoprecipitations identify genes mediating cell-cycle arrest and apoptosis 
as direct targets of miR-22. REDD1, TP53INP1, p21, and CARF transcripts show 
significantly higher Ago2 occupancy in miR-22 transfected HeLa cells compared to 
mock transfected cells. Ago2 occupancy of the target genes transcripts was measured 
using qRT-PCR as described in the text. The Y-axis shows fold change in mRNA levels 
from Ago2 IP isolated RNA normalized to input RNA, which served as the control. (B) 
Luciferase assays show that miR-22 directly targets the 3' UTRs of the genes indicated on 
the X-axis. IKKg and Empty are negative controls. IKKg was not repressed by miR-22 
and Empty is the luciferase vector with no UTR. The Y-axis shows relative luciferase 
units from miR-22 transfected cells normalized to control siRNA transfection. For the 
mutant 3’UTRs, three base pairs in each 6-mer miR-22 target site in the 3’UTRs were 
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Fig 2.6 continued. 
mutated. (C) qRT-PCR results for REDD1, TP53INP1, p21, and CARF transcripts show 
increased expression in quiescent fibroblasts relative to proliferating fibroblasts. Y-axis 
indicates fold enrichment in quiescent versus proliferating fibroblasts. (D) qRT-PCR 
shows miR-22 suppresses TP53INP1, REDD1 and p21 transcript levels in quiescent 
fibroblasts. Fold changes are denoted on the Y-axis relative to the control siRNA 
transfection. (E) REDD1, TP53INP1, p21, and CARF protein expression in fibroblasts 
was down-regulated by transfection with miR-22 compared to control siRNA 
transfection. For A, C, and D, GAPDH was used as a control for normalizing input RNA 
levels. For A, B, C, and D bars indicate the mean, and error bars denote ± s.d., n=3. P-
values were estimated by Student’s t-test. *, P<0.05 
2.4.4 miR-22 targets genes that regulate the interferon response 
Remarkably, 25 out of the top 50 genes identified by microarray to be down 
regulated by miR-22 in quiescent fibroblasts were interferon inducible genes (Figure 2.7). 
However, most of the interferon response genes that were repressed by miR-22 under 
quiescence did not show matches to the miR-22 seed sequence in their 3' UTRs (Figure 
2.7), suggesting that the down regulation of the majority of these genes in response to 
miR-22 was occurring through an indirect mechanism. 
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Figure 2.7 miR-22 represses genes mediating interferon suppression. 
The interferon response pathway. Green indicates genes in the pathway that were 
repressed by miR-22 in quiescent fibroblasts but have no predicted miR-22 target sites; 
orange indicates genes repressed by miR-22 in quiescent fibroblasts and have predicted 
miR-22 target sites; blue indicates genes that have predicted target sites but were not 
repressed by miR-22 in quiescent fibroblasts. Genes in grey don't meet any of these 
criteria. 
 
To identify the direct targets of miR-22 that mediate suppression of interferon 
genes, we used Ago2 IPs. We screened several candidate target genes that had 
established roles in activating the interferon pathway and were potential miR-22 targets 
based on the presence of the miR-22 seed sequence in their 3' UTRs. From this screen we 
identified two target genes, HMGB1 and IRF5, which showed increased occupancy by 
Ago2 in miR-22 transfected cells compared to control, and had established roles in 
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activating the interferon pathway (Figure 2.7 & 2.8A). Both HMGB1 and IRF5 have 
multiple miR-22 seed match sequences in their 3' UTRs, and HMGB1 was predicted to 
be a miR-22 target by RNA22 (62) while IRF5 was predicted to be a target of miR-22 by 
TargetScan (24). Other candidate genes in the interferon response pathway, which also 
contained miR-22 seed matches in their 3' UTRs, did not show increased Ago2 
occupancy (data not shown), indicating that this assay identified specific targets. To 
verify that these targets identified by Ago2 IPs could be repressed by miR-22, we cloned 
the 3' UTRs of HMGB1 and IRF5 into luciferase reporters to assay repression by miR-22. 
The 3' UTRs of both genes were indeed repressed by miR-22, and introducing mutations 
into the predicted miR-22 target sites relieved repression, confirming that miR-22 directly 
targets HMGB1 and IRF5 (Figure 2.8B). Additionally, the transcript levels of both of 
these genes were suppressed by miR-22 overexpression in HeLa cells, and protein 
expression was repressed by miR-22 overexpression in quiescent primary human 
fibroblasts (Data not shown & Figure 2.8C). Surprisingly, neither IRF5 or HMGB1 were 
among the many interferon genes that showed strongly decreased expression in HeLa 
cells transfected with miR-22 as determined by microarray profiling (Figure 2.8). We 
assayed transcript and protein levels for both HMGB1 and IRF5 in proliferating 
compared to quiescent primary human fibroblasts by qRT-PCR and western. Only IRF5 
was significantly repressed at both the transcript and protein level in proliferating 
compared to quiescent cells (Figure 2.8D & 2.8E). 
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Figure 2.8 miR-22 target genes mediating interferon suppression. 
(A) Ago2 immunoprecipitations identify HMGB1 and IRF5 as direct miR-22 targets. 
HMGB1 and IRF5 transcripts show significantly higher Ago2 occupancy in miR-22 
transfected HeLa cells compared to mock transfected cells. Ago2 occupancy of the target 
genes transcripts was measured using qRT-PCR as described in the text. The Y-axis 
shows fold change in mRNA levels from Ago2 IP isolated RNA normalized to input 
RNA. (B) Luciferase assays show that miR-22 directly targets the 3’UTRs of HMGB1 
and IRF5. The Y-axis indicates relative luciferase units normalized to the control siRNA 
transfection. IKKg and Empty are negative controls. IKKg was not repressed by miR-22 
and Empty is the luciferase vector with no UTR. For the mutant 3’UTRs, three base pairs 
in each 6-mer miR-22 target site in the 3’UTRs were mutated. (C) IRF5 protein 
expression in fibroblasts was down regulated by transfection with miR-22 compared to 
control siRNA transfection. (D) Increased expression of IRF5 in quiescent fibroblasts 
relative to proliferating fibroblasts assayed by qRT-PCR. Y-axis indicates fold 
enrichment in quiescent versus proliferating fibroblasts. (E) IRF5 protein expression was 
increased in quiescent compared to proliferating fibroblasts. For B and E, GAPDH was 
used as a control for normalizing input RNA levels. For A, B, and D bars are the mean, 
error bars denote ± s.d., n=3. For A, B, and D P-values were estimated by Student’s t-test. 
*, P<0.05.  
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2.4.5 miR-22 suppresses the interferon response 
Both IRF5 and HMGB1 mediate interferon signaling pathways. IRF5 (interferon 
regulatory factor-5) is involved in the induction of proinflammatory cytokines in 
response to several different TLR (Toll-like receptor) ligands and mediates signaling 
downstream of the TLR7 and TLR8 pathways to activate the interferon-beta promoter 
(63, 64). HMGB (high mobility group box) proteins are highly represented in the nucleus 
and are responsible for regulating transcription and chromatin structure (65). However, 
HMGB1 was recently shown to act as a universal sensor for double-stranded RNA as 
well as DNA and stimulate the interferon pathway by activating the transcription factors 
IRF3 and NF-κB, which are essential components of the interferon-beta promoter 
“enhanceosome”. Additionally, HMGB1 deficient fibroblasts (Hmgb1 -/-) show 
significantly impaired type-I interferon induction (66).  
To establish whether miR-22 was able to functionally suppress HMGB1 and IRF5 
activated interferon-signaling pathways, we examined the response of NF-κB and IRF3 
to miR-22 after we artificially activated the interferon pathway using poly I:C. Poly I:C is 
a double-stranded RNA polymer that mimics a viral infection and induces a strong type I 
interferon response(67). HMGB1 and IRF5 have been shown to mediate the activation of 
the transcription factors NF-κB and IRF3, both of which are key regulators of the 
interferon response (66, 68). Using a reporter of NF-κB activation we confirmed that 
miR-22 inhibits NF-κB activation in response to a trigger of interferon activation (Figure 
2.9A). miR-22 also suppressed IRF3 phosphorylation, a hallmark of IRF3 activation, in 
response to activation of the interferon response (Figure 2.9B). To further characterize 
miR-22 mediated suppression of interferon pathway genes, we asked whether miR-22 
could suppress an induced interferon response. We co-transfected miR-22 duplexes and 
poly I:C into HeLa cells and harvested cells 12 hours later. Induction of the type I 
interferon response was measured by assaying IFNB1 and several other ISG mRNA 
levels by qRT-PCR. Co-transfection of miR-22 severely impaired normal IFNB1 and 
subsequent ISG induction by poly I:C (Figure 2.9C). These results strongly indicated that 
miR-22 was able to suppress the type I interferon response. 
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Figure 2.9 miR-22 suppresses the interferon response. 
(A) miR-22 inhibits NF-κB activation as measured by reporter activity. Columns 
correspond to transfections of Poly I:C and miR-22 or control siRNA as indicated under 
the X-axis. Poly I:C was used to trigger the interferon response. Bars indicate the mean, 
error bars denote ± s.d., n=3. *, P<0.05. (B) miR-22 inhibits IRF3 activation. Western 
blot assay for the phosphorylated form of IRF3 shows that miR-22 prevents IRF3 
activation as compared to the control. Transfections of Poly I:C and miR-22 or control 
siRNA were as indicated. (C) miR-22 suppresses a poly I:C induced interferon response. 
Poly I:C was cotransfected in HeLa cells with either miR-22 or the negative control 
siRNA. miR-22 suppression of the poly I:C induced interferon pathway was assayed by 
measuring inhibition of interferon-beta (IFNB1) and several other ISGs, using qRT-PCR. 
The Y-axis indicates relative transcript levels normalized to control. Data shown is a 
representative experiment of two biological replicates measured in triplicate, (mean ± 
s.d.). GAPDH was used as a control for normalizing input RNA levels. 
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These results combined with the observed down regulation of many interferon 
response genes with miR-22 overexpression in quiescent cells suggested that interferon 
response genes were active in quiescent cells, and that miR-22 was capable of repressing 
the interferon response pathway. Previous cDNA profiling studies in quiescent fibroblasts 
have noted that interferon response genes are activated as fibroblasts enter quiescence 
(69). To confirm that interferon response genes were activated under quiescence, we 
measured relative mRNA expression levels of interferon beta-1 (IFNB1), a key marker 
and inducer of the Type I interferon response, as well as several interferon stimulated 
genes (ISGs) in proliferating and quiescent fibroblasts. All of the interferon genes that we 
tested were expressed at higher levels in quiescent cells (Figure 2.10A). The interferon 
response is potently antiproliferative (70), and the elevated expression of interferon genes 
could potentially be part of intrinsic mechanisms maintaining cellular quiescence. 
To verify that an active interferon response would be detrimental to proliferation, 
we artificially activated the interferon pathway by transfecting poly I:C into quiescent 
fibroblasts, then stimulated them with serum to induce proliferation and assayed 
expression of proliferation marker Ki67. Quiescent fibroblasts that were not treated with 
poly I:C showed efficient exit from quiescence into a proliferative state as measured by 
Ki67 expression levels (Figure 2.10B). However, poly I:C treated quiescent fibroblasts 
showed no change in Ki67 expression levels indicating that a heightened interferon 
response inhibited transition into a proliferative state (Figure 2.10B). 
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Figure 2.10 The type I interferon pathway in quiescence. 
(A) The type I interferon pathway is activated in quiescent cells. The column graph 
shows qRT-PCR data for expression levels of IFNB1 and other ISGs in the type I 
interferon pathway in quiescent fibroblasts relative to proliferating fibroblasts. The Y-
axis indicates relative transcript levels in quiescent fibroblasts normalized to proliferating 
fibroblasts. Relative transcript levels in proliferating fibroblasts are shown by the dashed 
line. Bars indicate the mean, error bars denote ± s.d., n=3. *, P<0.05. (B) Active 
interferon pathway impairs the transition from quiescence to proliferation. The interferon 
pathway was activated by transfecting quiescent fibroblasts with poly I:C, and then 
treated cells were serum-stimulated to proliferate. Cells were harvested at the time points 
indicated in hours on the X-axis. Q: quiescent fibroblasts. Cell proliferation was assayed 
by measuring Ki67 transcript levels using qRT-PCR. Relative Ki67 expression as 
indicated on the Y-axis, was calculated with respect to untreated quiescent fibroblasts. 
Data shown is a representative experiment measured in triplicate, (mean ± s.d.). For A 
and B, GAPDH was used as a control for normalizing input RNA levels.  
2.4.6 Myc activates miR-22 during the transition from quiescence to proliferation 
Interestingly, miRNA expression profiling of serum stimulated primary human 
fibroblasts also showed miRNAs from the miR-17-92 cluster were induced along with 
miR-22 during the serum stimulated transition from quiescence to proliferation (Figure 
2.11A). The miR-17-92 cluster has been shown to be directly activated by the 
transcription factor Myc (71). To investigate whether miR-22 and other serum-stimulated 
miRNAs were also regulated by Myc, we first overexpressed or knocked down Myc in 
HeLa cells and assayed the resulting changes in miRNA levels using microarrays. miR-
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22, and the known targets of Myc, miR-17 and miR-92, were activated by Myc 
overexpression and were repressed by Myc knockdown (Figure 2.11A). To examine Myc 
regulation of miR-22 in primary human fibroblasts, Myc was knocked down by siRNA in 
proliferating primary human fibroblasts and in primary human fibroblasts exiting 
quiescence. Proliferating fibroblasts with Myc knocked-down showed a significant 
decrease in miR-22 expression compared to control (Figure 2.11B & C). qRT-PCR for 
Myc expression confirmed Myc activation in response to serum stimulation of 
fibroblasts, at time points very similar to miR-22 induction (Figure 2.11D). This pattern 
of miR-22 expression in response to serum stimulation and modulation of Myc activity 
suggested that miR-22 may be activated by Myc. 
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Figure 2.11 Myc activates miR-22 during the transition from quiescence to proliferation. 
(A) Heat map showing the response of miRNAs to Myc overexpression (OE), and Myc 
knockdown (KO) in HeLa cells, and to serum stimulation of quiescent fibroblasts (SS) 
measured using microarrays. Ratios displayed under the SS column represent the 
maximum activation across all measured time-points (5, 10, 20, 30, 60, and 180 minutes) 
after serum stimulation. miR-17 and miR-92 are previously known downstream targets of 
Myc. (B) miR-22 expression is inhibited by Myc knockdown in proliferating fibroblasts. 
miR-22 expression was assayed by qRT-PCR in fibroblasts transfected with an siRNA 
against Myc or a control siRNA. Relative expression values were normalized to those 
obtained using the control siRNA (Y-axis). Bars indicate the mean and error bars denote 
± s.d., n=3. *, P < 0.05. (C) Western blot of Myc knockdown by an siRNA against Myc. 
(D) Independent qRT-PCR verification of Myc expression during the transition from 
quiescence to proliferation. The Y-axis shows expression after serum stimulation relative 
to quiescence at each of the indicated time points on the X-axis. Data shown is for a 
representative experiment measured in quadruplicate (mean ± s.d.). GAPDH was used as 
a control for normalizing input RNA levels. 
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In order to investigate whether Myc directly activates miR-22 by binding to 
upstream cis-regulatory sequences, we examined genome-wide Myc ChIP-sequencing 
(ChIP-seq) data generated in our lab from serum stimulated fibroblasts as well as HeLaS3 
and MCF7 cells (72). In all cell types, particularly in the rapidly proliferating HeLaS3 
and MCF7 cells, we observed Myc binding at several sites around the predicted 
transcription start site (TSS) of miR-22 (73) (Figure 2.12A). Myc is known to bind its 
chromosomal target sites in mammalian cells, including human fibroblasts, through a 
DNA motif known as the E-box (48). Motif analysis of the region upstream of miR-22 
revealed phylogenetically conserved E-box elements within the Myc-binding sites that 
we identified by ChIP-seq, many of which occurred within CpG islands (Figure 2.12A). 
Phylogenetic conservation of putative regulatory elements is frequently an indication of 
functional significance, and the genomic binding of Myc is known to be associated with 
the proximal presence of CpG islands (74). As an example, we verified Myc binding to 
one of the sites detected by ChIP-seq in an independent experiment by carrying out ChIP-
qPCR in fibroblasts that were induced to proliferate (Figure 2.12B). In addition, 
luciferase promoter reporter assays using Myc binding regions upstream of miR-22 
showed that Myc could functionally activate gene expression through one of these 
upstream promoter regions (L3) (Figure 2.12C). The L3 promoter region site contains 
two putative Myc binding site motifs (M1 and M2), but mutation of the putative Myc 
binding site motifs did not impair activation by Myc in the reporter assay in a consistent 
manner (Figure 2.12D). These results nevertheless show that miR-22 expression is 
responsive to Myc, and that Myc binds to the promoter of miR-22 and activates its 
transcription in a manner that is consistent with direct activation, both in HeLa cells as 
well as fibroblasts during their exit from quiescence. 
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Figure 2.12 Myc binding upstream of miR-22. 
(A) ChIP-seq data for Myc in HeLaS3, MCF7 and serum stimulated fibroblasts shows 
Myc binding upstream of miR-22. The profiles of overlapping extended ChIP-seq reads 
are indicated in green. Chromosome coordinates are indicated on top and genes are 
shown at bottom. MIR22HG refers to the primary miR-22 transcript as annotated in 
RefSeq, and the mature miR-22 sequence is indicated by a red symbol. Regions (L1-L4) 
subsequently tested for promoter activity in luciferase assays are shown by black 
rectangles, phylogenetically conserved E-boxes by vertical blue lines, and CpG islands 
and qPCR primer loci by vertical black lines. (B) ChIP-qPCR verification of Myc binding 
upstream of miR-22. An independent ChIP for Myc was performed in serum stimulated 
fibroblasts. Primers were designed to amplify two loci (F1 and F2) indicated as binding 
sites by ChIP-seq. Fold enrichment, indicative of Myc binding, was calculated relative to 
input DNA, normalized to a negative control region (Y-axis). The threshold for ChIP 
enrichment relative to the control is indicated by the red dashed line. (C) Promoter assays 
for 4 Myc putative promoter regions upstream of miR-22. L1 to L4 on the X-axis indicate 
cloned candidate promoter regions. P is a positive control. The Y-axis shows expression 
fold change of a luciferase promoter reporter normalized to a negative control vector. The 
 35 
Figure 2.12 continued. 
L3 region shows a significant increase in reporter activity when Myc is overexpressed. 
(D) Mutation of putative Myc binding sites M1 and M2 in the L3 promoter region. M1 + 
M2 indicates both sites were mutated. For C and D, grey bars indicate Myc 
overexpression and white bars indicate endogenous levels of Myc (Myc was not 
overexpressed). For B, C, and D bars indicate the mean and error bars denote ± s.d., n=3. 
For C and D *, P < 0.05. 
2.4.7 miR-22 inhibits the Myc repressor MXD4 
Another target of miR-22 that we identified was MXD4, a transcriptional 
repressor of Myc, which in turn is repressed by Myc (75, 76). We found that MXD4 
transcript levels were activated and Myc levels were suppressed when cells entered 
quiescence (Figure 2.13A). miR-22 transfection impaired MXD4 activation and Myc 
suppression under quiescence (Figure 2.13B). We verified using Ago2 IP and 3' UTR 
luciferase reporter assays that MXD4 was indeed a direct target of miR-22 (Figure 2.13C 
& D). Western blot confirmed miR-22 down-regulated MXD4 expression at the protein 
level in primary human fibroblasts (2.13E). These results suggest the existence of a 
feedback loop in which Myc activates miR-22 to suppress MXD4, which causes the up 
regulation of Myc expression. 
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Figure 2.13 miR-22 inhibits the Myc repressor MXD4. 
(A) qRT-PCR data showing MXD4 transcripts are activated while Myc transcript levels 
are inhibited in quiescent cells. qRT-PCR measurements of transcript levels in quiescent 
cells were made with respect to proliferating fibroblasts, as indicated on the Y axis. 
Relative transcript levels in proliferating fibroblasts are shown by the dashed line. Data 
shown are for a representative experiment of two biological replicates measured in 
triplicate. (B) miR-22 transfection impairs MXD4 activation and indirectly reduces Myc 
suppression in quiescent fibroblasts compared to control siRNA transfection. (C) Ago2 
immunoprecipitations identify MXD4 as a direct target of miR-22. MXD4 transcripts 
showed higher Ago2 occupancy in miR-22 transfected HeLa cells compared to mock 
transfected cells. Ago2 occupancy of the target genes transcripts was measured using 
qRT-PCR as described in the text. The Y-axis shows fold change in mRNA levels from 
Ago2 IP isolated RNA normalized to input RNA. (D) Luciferase assays confirm that 
Myc-binding sites does not conclusively support direct ac-
tivation (29). Taken together, our data demonstrate novel
interaction between the p53 and Myc regulatory networks
that is mediated by miR-22 (Figure 7). We postulate that
the combined effect of inhibiting interferon and cell-cycle
arrest pathways downstream of p53 enables miR-22 to
induce quiescent fibroblasts to proliferate.
Recently, other groups have reported that miR-22 acts
like a proto-oncogene promoting proliferation and
invasion of cancer cells by inhibiting the tumor-suppressor
PTEN (21,24,25). On the other hand, other recent studies
have reported that miR-22 inhibits proliferation of cancer
cell lines (not including the ones we have tested) by in-
hibiting MAX (27) and MYCBP (28,29). However, we
observed no inhibitory effect of miR-22 in primary cells
or HeLa cells (data not shown), and in fact observed a
modest activation of proliferation marker Ki67 by miR-22
in proliferating fibroblasts, consistent with our other
results (Supplementary Figure S1). We found that
miR-22 indirectly upregulates Myc expression levels by
inhibiting the Myc transcriptional repressor MXD4, thus
participating in a regulatory feedback loop (Figure 7).
Other groups observed inhibition of Myc by miR-22 re-
pression of Myc-binding partners MAX or MYCBP in
cancer cell lines, suggesting miR-22 may activate or
repress Myc activity depending on cell type (27,29).
Because haploinsufficiency of Myc leads to impairment
of proliferation, a small change in Myc expression can
be expected to have significant outcomes on cell-cycle pro-
gression. The above results taken together raise the
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Figure 6. miR-22 inhibits the Myc repressor MXD4. (A) qRT-PCR data showing MXD4 transcripts are activated while Myc transcript levels are
inhibited in quiescent cells. qRT-PCR measurements of transcript levels in quiescent cells were made with respect to proliferating fibroblasts, as
indicated on the Y-axis. Relative transcript levels in proliferating fibroblasts are shown by the dashed line. Data shown are for a representative
experiment of two biological replicates measured in triplicate. Data from an independent replicate are shown in Supplementary Figure S7.
(B) miR-22 transfection impairs MXD4 activation and indirectly reduces Myc suppression in quiescent fibroblasts compared with control siRNA
transfection. (C) Ago2 IPs identify MXD4 as a direct target of miR-22. MXD4 transcripts showed higher Ago2 occupancy in miR-22-transfected
HeLa cells compared with mock-transfecte cells. Ago2 occupancy of the target gen s transcripts was me sured using qRT-PCR as described in the
text. The Y-axis shows fold change in mRNA levels from Ago2 IP–isolated RNA normalized to input RNA. (D) Luciferase assays confirm that
miR-22 directly targets the 30UTR of MXD4. The Y-axis indicates relative luciferase units from miR-22-transfected cells normalized to control
siRNA-transfected cells. IKKg and Empty are negative controls, IKKg was not repressed by miR-22 and Empty is the luciferase vector with no
UTR. For the mutant 30UTRs, 3 bp in each 6-mer miR-22 target site in the 30UTRs were mutated. (E) MXD4 protein expression in fibroblasts was
downregulated by transfection with miR-22 compared with control siRNA transfection. For A, B and C, GAPDH was used as a control to
normalize input RNA levels. For B, C and D, bars indicate the mean, and error bars denote ±SD, n=3. P-values were estimated by Student’s
t-test. *P< 0.05.
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Figure 2.13 continued. 
miR-22 directly targets the 3’UTR of MXD4. The Y-axis indicates relative luciferase 
units from miR-22 transfected cells normalized to control siRNA transfected cells. IKKg 
and Empty are negative controls, IKKg was not repressed by miR-22 and Empty is the 
luciferase vector with no UTR. For the mutant 3’UTRs, three base pairs in each 6-mer 
miR-22 target site in the 3’UTRs were mutated. (E) MXD4 protein expression in 
fibroblasts was down-regulated by transfection with miR-22 compared to control siRNA 
transfection. For A, B, and C, GAPDH was used as a control to normalize input RNA 
levels. For B, C, and D bars indicate the mean and error bars denote ± s.d., n=3. P-values 
were estimated by Student’s t-test. *, P<0.05.  
2.5 DISCUSSION 
Our results show a TF-miRNA network that is activated as primary fibroblasts 
exit quiescence and re-enter the cell cycle. The oncogenic transcription factor Myc binds 
upstream of miR-22 and activates miR-22 expression when quiescent fibroblasts are 
stimulated to proliferate. In addition, we show that miR-22 promotes proliferation in 
primary human fibroblasts, and we identified targets of miR-22 that include several cell 
cycle arrest genes, REDD1, TP53INP1, p21, and CARF, as well as MXD4 which 
represses Myc. Although the effect of miR-22 on the protein levels of cell cycle arrest 
genes was modest, moderate regulation of multiple cell cycle arrest genes may have large 
phenotypic effects in concert. We also found that miR-22 targets genes that mediate the 
interferon response, HMGB1 and IRF5, and that miR-22 repressed the interferon 
response. 
The early activation of miR-22 we observed as cells exit quiescence and re-enter 
the cell cycle may be rationalized in terms of its effect on the interferon response and cell 
cycle arrest genes. Although the interferon response is known to be antagonistic to cell 
proliferation, the exact role of the interferon response genes during quiescence is unclear 
(70). It has been suggested that signaling pathways actively maintain cells in a viable, 
reversibly arrested stage (1). It is possible that high levels of interferon response genes 
are required for maintaining or inducing a state of cell-cycle arrest in quiescent cells. 
Indeed, up-regulation of interferon response genes in cells entering quiescence has been 
observed, and interferon has long been known to repress proliferation in fibroblasts (69, 
77). Consequently, in order to exit quiescence and begin to proliferate, cells must 
 38 
overcome this inhibitory influence on proliferation. When we artificially up regulated the 
interferon pathway under quiescence, entry into proliferation in response to serum-
stimulation was severely impaired. One of the means by which cells may overcome this 
inhibitory effect is to use an immediate-early transcription factor like Myc to activate a 
suppressor of the interferon pathway, namely the miRNA miR-22 (Figure 2.14). We 
found that miR-22 functionally inhibits NF-κB and IRF3 activation by directly targeting 
and down regulating HMGB1 and IRF5, which are known activators of the interferon 
activation pathway, thus identifying the molecular basis of how miR-22 mediates 
interferon suppression. In addition, HMGB1 has recently been shown to regulate 
proliferation, and influences both wound healing and cancer progression (1, 76). 
Surprisingly, HMGB1 was not downregulated in quiescent primary human fibroblasts. 
However, IRF5 was downregulated in quiescent primary human fibroblasts, indicating 
that the interferon mediated maintenance of quiescence may only be regulated by IRF5 in 
primary human fibroblasts. 
We also present evidence that reveals novel cross talk between the p53 and Myc 
regulatory networks that is mediated by mir-22. We show that miR-22 targets cell-cycle 
arrest pathways that are mediated by the tumor suppressor p53. IRF5 is known to be a 
direct target of p53 and promotes cell-cycle arrest and cell death (78, 79). IRF5 also 
induces senescence when overexpressed in immortalized Li-Fraumeni fibroblasts (80). 
Additionally, we find that miR-22 directly inhibits other pro-apoptotic and cell-cycle 
arrest genes such as REDD1, TP53INP1, p21 and CARF that are also direct targets of or 
regulate p53 (Figure 2.14). Interestingly, miR-22 itself is known to be a direct target of 
p53, and miR-22 determines p53-dependent cellular fate through direct regulation of p21 
(43). In addition, previous studies have shown a p53-dependent suppression of Myc at the 
transcriptional and post-transcriptional level (81, 82). Furthermore, our data show 
upstream binding and activation of miR-22 by Myc. A group previously observed similar 
results and concluded that this indicated direct activation of miR-22 by Myc, but our 
further analysis of Myc binding sites does not conclusively support direct activation (44). 
Taken together, our data demonstrate novel interaction between the p53 and Myc 
regulatory networks that is mediated by miR-22 (Figure 2.14). We postulate that the 
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combined effect of inhibiting interferon and cell cycle arrest pathways downstream of 
p53 enables miR-22 to induce quiescent fibroblasts to proliferate. 
Recently, other groups have reported that miR-22 acts like a proto-oncogene 
promoting proliferation and invasion of cancer cells by inhibiting the tumor suppressor 
PTEN (39-41). On the other hand, other recent studies have reported that miR-22 inhibits 
proliferation of cancer cell lines (not including the ones we have tested) by inhibiting 
MAX (42) and MYCBP (43, 44). However, we observed no inhibitory effect of miR-22 
in primary cells or HeLa cells (data not shown), and in fact observed a modest activation 
of proliferation marker Ki67 by miR-22 in proliferating fibroblasts, consistent with our 
other results (Figure 2.3). We found that miR-22 indirectly up regulates Myc expression 
levels by inhibiting the Myc transcriptional repressor MXD4, thus participating in a 
regulatory feedback loop (Figure 2.14). Other groups observed inhibition of Myc by miR-
22 repression of Myc binding partners MAX or MYCBP in cancer cell lines, suggesting 
miR-22 may activate or repress Myc activity depending on cell type (42, 44). Since 
haploinsufficiency of Myc leads to impairment of proliferation, a small change in Myc 
expression can be expected to have significant outcomes on cell cycle progression. The 
above results taken together raise the intriguing possibility that miR-22 may act as a 
switch inducing or inhibiting cellular proliferation in a context dependent manner. This 
study provides evidence that miRNAs up regulated during the transition of quiescent cells 
into a proliferative state have a defined functional role in reprogramming gene expression 
to enable the transition of G0 arrested cells into the cycling G1 stage. Furthermore, our 
results provide evidence of the complex interplay between transcription factors and 
miRNAs to transduce extracellular signals into physiological responses. 
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Figure 2.14 The anti-quiescence network mediated by the Myc-miR-22 pathway. 
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Chapter 3 miR-191 regulates human cell proliferation and directly 
targets multiple oncogenes. 
3.1 ABSTRACT 
miRNAs play a central role in numerous pathologies including multiple cancer 
types. miR-191 has predominantly been studied as an oncogene, but the role of miR-191 
in primary cell proliferation is not well characterized, and the transcriptome wide targets 
of miR-191 have not been experimentally determined. Here we utilized RNA silencing 
complex immunoprecipitations as well as gene expression profiling to construct a 
transcriptome wide miR-191 target set. We showed that miR-191 represses proliferation 
in primary human cells, and targets multiple proto-oncogenes, including CDK9, 
NOTCH2, and RPS6KA3. Our results provided an extensive transcriptome wide set of 
targets for miR-191, and demonstrated the cell type specific nature of miR-191’s 
regulation of proliferation in non-small cell lung cancer.  
3.2 INTRODUCTION 
miR-191 has previously been shown to play a role in multiple types of cancer, 
including gastric, colorectal, breast, thyroid, and hepatocellular carcinoma (83-87). 
Proliferation related targets have also been identified for miR-191, such as CDK6 and 
SATB1 (88). Despite the clear link between miR-191, proliferation, and tumorigenesis, 
the regulation of proliferation by miR-191 has not been explored in primary cells, and 
transcriptome wide target identification for miR-191 has not been performed with current 
biochemical techniques. 
In this study, we investigated the regulation of cell proliferation in primary human 
cells by miR-191. We experimentally identified the targets of miR-191 by conducting 
extensive profiling of RISC associated transcripts and gene expression profiling. GO-
term enrichment analysis of these targets identified multiple genes involved in 
proliferation and cell cycle regulation, and we experimentally confirmed multiple proto-
oncogenes as direct targets of miR-191. Finally we showed that miR-191 mediates non-
small cell lung cancer (NSCLC) proliferation in a cell type dependent manner.  
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3.3 MATERIALS AND METHODS 
3.3.1 Normal cell culture conditions 
Cells were cultured as described in Chapter 2 Materials and Methods 2.3.9. 
3.3.2 RNA oligos and transfections 
miRNA and LNA oligos were prepared and transfected as described in Chapter 2 
Materials and Methods 2.3.9. An additional Control siRNA oligo was used, Control 
siRNA 2, adapted from. 
3.3.3 Cell counting assays 
For miRNA overexpression experiments, fibroblasts were seeded at 10,000 cells 
per well in 6-well plates. Cells were cultured in DMEM supplemented with 10% FBS. 
Cells were allowed to grow 24 hours, and then cells were transiently transfected with 
miR-191 or siGFP duplexes (100 nM final concentration). 0, 24, 48, 72, and 96, hours 
after transfection, cells were trypsinized, and counted in a hemacytometer. 9 fields were 
averaged for each biological replicate. For miRNA inhibition experiments, fibroblasts 
were seeded at 10,000 cells per well in 6-well plates. Cells were cultured in DMEM 
supplemented with 10% FBS. Cells were allowed to grow 24 hours, and then media was 
replaced with low serum DMEM 0.1% FBS. 24 hours after replacement with DMEM 
0.1% FBS, cells were transiently transfected with miR-191 miRCURY Locked Nucleic 
Acid (LNA) miRNA Inhibitor and Negative Control Inhibitor obtained from Exiqon (10 
nM final concentration). 0, 24, and 48 hours after transfection, cells were trypsinized, and 
counted in a hemacytometer. 9 fields were averaged for each biological replicate. 
3.3.4 Flow cytometry 
Fibroblasts were seeded at 50,000 cells per well in 6 well plates. Cells were 
cultured in DMEM supplemented with 10% FBS. Cells were allowed to grow 24 hours, 
and then cells were transiently transfected with miR-191, control siRNA, or Control 
siRNA 2 duplexes (100 nM final concentration). 24 hours after transfection, cells were 
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trypsinized, washed with PBS, and fixed for 24 hours in 70% ethanol at -20°C. For Ki67 
combined with PI staining, after ethanol fixation, cells were washed with Stain Buffer 
(BD Pharmingen), incubated 30 minutes with FITC Mouse Anti-Human Ki67 antibody 
(BD Pharmingen), washed, and resuspended in 500 µl Stain Buffer with Propidium 
Iodide Staining Solution (5 µg/ml) (BD Pharmingen). For PI staining alone, after ethanol 
fixation, cells were washed twice with PBS, then resuspended in PI staining solution 
(50ug/mL PI with 100ug/mL RNase in PBS). Flow cytometry analysis for Ki67 in 
primary human fibroblasts was done using a FACsCalibur flow cytometer and 10,000 
events above threshold levels were counted for each sample (BD Biosciences). Data 
analysis was done using FlowJo. Flow cytometry analysis for Ki67 in cancer cell lines 
was done using a BD Accuri flow cytometer and 10,000 events above threshold levels 
were counted for each sample (BD Biosciences). 
3.3.5 RISC immunoprecipitation 
We adapted the protocol developed by Hendrickson et. al. (52) for 
immunoprecipitating Ago2-mRNA complexes. Ago2 is an essential component of RISC. 
Briefly, HeLa cells were grown in 10 cm2 tissue culture plates and transfected with either 
miRNA mature duplexes or siGFP duplexes at a final concentration of 100 nM or mock 
transfected. After 24 hours, cells were washed twice with PBS, and 0.5 ml of lysis buffer 
was added onto the cell monolayer followed by incubation at 4°C for 30 minutes. Cell 
lysate was collected by scrapping and cleared by centrifugation at 14,000 rpm at 4°C. 
Cleared lysate was then incubated with 50 µl of protein-G beads (Roche) for 1 hour at 
4°C (pre-clearing). Before pre-clearing, 50 µl of the cleared lysate was removed as input 
for total RNA profiling. Pre-cleared lysate was incubated with 15 µg of Ago2 antibody 
(ab57113, Abcam) and incubated at 4°C for 3 hours. After antibody incubation, 50 µl of 
protein-G beads were added to the lysate and incubated for 1 hour at 4°C. Beads were 
washed 8 times with lysis buffer and Ago2-RNA complexes were extracted by adding 1 
ml TRIzol reagent (Invitrogen) directly to the beads. RNA extraction was carried out as 
per the manufacturers instructions. 
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3.3.6 RNA-seq library preparation 
rRNA was removed using the Ribo-Zero rRNA Removal Kit (Epicentre), and the 
rRNA removal reaction was cleaned using the RNeasy MinElute Cleanup Kit (Qiagen). 
RNA was then fragmented using the NEBNext Magnesium RNA Fragmentation Module 
(New England BioLabs), and size selected using AMPure XP beads (Agencourt) at 1.8X 
volume. The ends of the fragmented RNA were then prepared for adaptor ligation using 
T4 Polynucleotide Kinase (New England BioLabs), and the reaction was cleaned up with 
the RNeasy MinElute Cleanup Kit (Qiagen). Libraries were then prepared from the now 
rRNA depleted, fragmented, size selected, and kinased RNAs using the NEBNext Small 
RNA Library Prep Set according to the manufacturers protocol (New England BioLabs). 
Libraries were cleaned and further size selected using 0.8X volume AMPure XP beads, 
and then additional size selections with 1.0X beads were performed as necessary. At least 
20 million paired end 100bp reads were generated for each replicate using a HiSeq 2000 
(Illumina) by the Genomic Sequencing and Analysis Facility at the University of Texas at 
Austin. 
3.3.7 RNA-seq data processing 
Barcodes were removed, adaptors were removed using Cutadapt, and reads 
mapping to rRNAs and tRNAs were filtered. Reads were mapped to the human genome 
(hg19) by TopHat2 software version 2.0.9 (89). We combined biological replicates and 
assigned an expression value (FPKM) for each RefSeq gene with Cuffdiff (89). Too 
avoid denominator inflation in subsequent ratio calculations, all FPKMs less then 1 were 
hard capped to 1.  
3.3.8 RNA-seq gene expression repression 
Repression of gene expression for each gene was calculated as the ratio of the 
FPKM in the miRNA transfection to the FPKM in the control transfection: 
Repression = FPKM for the control  
FPKM for the miRNA 
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3.3.9 RNA-seq RNA induced silencing complex immunoprecipitation enrichment 
 RNA-seq RNA induced silencing complex immunoprecipitations (RIP) 
enrichment was calculated as follows: RIP FPKMs were first normalized to gene 
expression FPKMs, and then enrichment was calculated as the ratio of the normalized 
miRNA transfection to the normalized control transfection: 
Enrichment = FPKM for the miRNA RIP / FPKM for the miRNA gene expression 
FPKM for the control RIP / FPKM for the control gene expression 
3.3.10 Defining a miRNA target list using RIP enrichment and gene expression 
repression 
 mRNAs were ranked by averaging RIP enrichment values and gene expression 
repression values to make a target score. mRNAs with a score of 1.5 or greater were 
designated as the target set.  
3.3.11 Gene Ontology analysis 
 Gene ontology analysis was performed with the GeneCodis online tool (90-92). 
3.3.12 Luciferase reporter assays 
Entire 3' UTRs or at least 0.5 kb up- and down-stream of the predicted miR-191 
binding site (whichever was shorter) were produced by PCR from human genomic DNA 
and inserted into the psi-CHECK2 plasmid using XhoI and NotI restriction sites 
downstream from the Renilla luciferase gene (Promega). For each plasmid produced this 
way, a mutant plasmid was subsequently made via deletion of the 22 bp sequence 
corresponding to the full position of miR-191 at the putative binding site (QuikChange 
Lightning Mutagenesis Kit, Agilent). 
HEK293 cells were plated in 24-well plates at 105 cells/well in DMEM 
supplemented with 10% FBS and 1% Pen-Strep and grown overnight (Hyclone, Gibco). 
Each plasmid was co-transfected at 50 ng/well with either miR-191 or siGFP at a 100 nM 
in triplicate (Lipofectamine, Invitrogen). Cells were harvested 24 hours post-transfection 
and luciferase activity was measured using the Promega Dual Luciferase kit according to 
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manufacturer’s instructions. Data was first normalized per-well by dividing Renilla 
luminescence by Firefly luminescence. Then, the mean of the three biological replicates 
for each miR-191 transfected group was divided by the mean of its corresponding siGFP 
transfected group, and the results were displayed in bar graphs grouped by plasmid.  
3.3.13 Quantitative Reverse-Transcription PCR for interferon stimulated genes 
RNA from quiescent and proliferating fibroblasts was extracted with the TRIzol 
reagent (Invitrogen) and reverse transcribed the High-Capacity cDNA Reverse 
Transcription Kit from ABI that uses random hexamers. PCR was performed using the 
SYBR GREEN PCR Master Mix from Applied Biosystems. The target gene mRNA 
expression was normalized to the expression of GAPDH and relative mRNA fold 
changes were calculated by the ΔΔCt method. 
3.3.14 Western blotting 
For western blots of putative miR-191 targets, primary human fibroblasts or HeLa 
cells were seeded in 6-well plates at 5 x 104 cells/well in DMEM supplemented with 10% 
FBS (Hyclone, Gibco). 24 hours after plating, miR-191 or si-GFP was transfected at a 
100 nM concentration (Lipofectamine, Invitrogen). Transfected cells were lysed at 24 hr, 
48 hr, 72 hr, or 96 hr post-transfection. 
Cell lysates were separated on 4-20% gradient SDS-PAGE gels (Biorad) and 
proteins were transferred onto PVDF membranes. Membranes were blocked with 5% 
milk or 5% BSA in TBST and probed overnight with primary antibody in blocking 
solution (AGO2: 1/1000, Abacam, ab57113; CDK9: 1/1000, Abcam, ab76320; 
NOTCH2: 1/500, ab8926; RPS6KA3: 1/1000, Abcam, ab75832; GAPDH: 1/1000, 
Abcam, ab9486). The membranes were washed, incubated with HRP-conjugated 
secondary antibody in blocking solution (1/5000, Santa Cruz Biotechnology, sc-2004), 
and washed again. HRP substrate solution was added to the membranes, and incubated 
for four minutes (Pierce). Blots were exposed to autoradiographic film and developed 
(Carestream Kodak Biomax). Images of the films were scanned and band intensities 
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quantified using a white-light transilluminator imaging system (FlourChem Q, 
ProteinSimple). 
3.3.15 Cancer survival analysis 
Survival probabilities of NSCLC patients were generated with MIRUMIR 
(http://www.bioprofiling.de/GEO/MIRUMIR/mirumir.html) (93). 
3.3.16 Statistical analysis 
Statistical significance was estimated using a one-sided, two sided, or paired 
Student’s t-test as indicated, and assuming unequal variance. 
3.4 RESULTS 
3.4.1 miR-191 represses primary human cell proliferation 
To investigate the role of miR-191 in primary human cell proliferation, we 
transiently overexpressed miR-191 by transfecting the mature duplex form of the miRNA 
into proliferating fibroblasts and assayed cell growth. miR-191 transfected cells showed 
significant reductions in cell growth rate compared to control (Figure 3.1). To confirm 
the effect of miR-191 on cell proliferation, we transfected miR-191 into proliferating 
fibroblasts and counted cells expressing the proliferation marker Ki67 protein using flow 
cytometry (53, 54). miR-34a, a well known tumor suppressor, served as a positive control 
(94). miR-191 transfection significantly decreased the percentage of Ki67 positive cells 
compared to multiple controls, indicating that miR-191 represses proliferation (Figure 
3.2). In addition, transfection of miR-191 into proliferating fibroblasts significantly 
decreased the rate of progression through the cell cycle (Figure 3.3). To rule out indirect 
effects from flooding the cells and the RNA silencing machinery with large amounts of 
the mature miRNA duplexes, we transiently inhibited miR-191 in fibroblasts induced into 
quiescence by serum removal. Inhibition of miR-191 in quiescent fibroblasts significantly 
increased the rate of cell growth (Figure 3.4). 
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Figure 3.1 miR-191 transfection reduces cell growth. 
Average cell number relative to 0hr following miR-191 or control siRNA transfection is 
shown for each time point indicated. Error bars denote ± SD, n = 4. P-values were 
estimated by Student’s t-test. *P < 0.05. 
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Figure 3.2 miR-191 transfection represses proliferation. 
Shown by flow cytometry analysis for expression of proliferation marker Ki67 in miR-
191 transfected fibroblasts. The Y-axis indicates the relative percentage of cells 
expressing Ki67. Bars are the mean percentage of cells expressing Ki67 relative to 
Control siRNA 2, and error bars denote ± SD, n = 3. P-values were estimated by 
Student’s one tailed t-test. *P < 0.05. 
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Figure 3.3 miR-191 transfection slows progression through the cell cycle. 
Show by flow cytometry analysis of cell cycle progression using propidium iodide 
staining of miR-191 transfected fibroblasts. The Y-axis denotes the percentage of cells 
found in each stage of the cell cycle, and bars are the mean percentage the cell population 
found in each stage. Error bars indicate ± SD, n = 3. P-values were estimated by 
Student’s paired t-test. *P < 0.05. 
 
 
 51 
 
Figure 3.4 Inhibition of miR-191 increases cell growth in quiescent. 
Fibroblasts were serum starved into quiescence. Average cell number relative to 0hr 
following transfection of an LNA targeting miR-191 or a LNA negative control is shown 
for each time point indicated. Error bars denote ± SD, n = 6. P-values were estimated by 
Student’s one tailed t-test. *P < 0.05. 
3.4.2 Transcriptome wide identification of miR-191 targets 
To experimentally identify the targets of miR-191 we used two approaches: (1) 
Profiling of transcripts isolated from RNA-induced silencing complex (RISC) 
immunoprecipitations (RIPs) following transient overexpression of miR-191, and (2) 
profiling gene expression following transient overexpression of miR-191 (Figure 3.5). 
RISC is directed to target mRNAs by the mature miRNA guide strand, and mediates 
repression of gene expression (23). To immunoprecipitate RISC, we used a monoclonal 
antibody directed against Argonaute-2, an essential component of RISC (23). Increases in 
RISC occupancy on a given transcript following miRNA overexpression indicate direct 
targets of the overexpressed miRNA. We profiled RISC occupancy by quantifying 
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transcripts isolated from RIPs using both microarrays (RIP-ChIP) and RNA-seq (RIP-
Seq). RIP Enrichment was defined as an increase in RISC occupancy on a given 
transcript following miRNA transfection compared to the control transfection. To obtain 
enough RNA for successful transcriptome wide profiling, all RIPs and gene expression 
experiments were conducted in HeLa cells, due to HeLa cells having a greater RNA 
content and being of a smaller size than human fibroblasts. 
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Figure 3.5 RISC associated RNA and total RNA samples from miRNA or Control 
siRNA transfected HeLas were isolated and profiled. 
There was strong correlation between RIP-Seq transcript levels and RIP-ChIP 
transcript levels, a well as gene expression profiled by RNA-seq and microarray (Table 
3.1 and Figure 3.6). No RIP Control siRNA comparison could be made because RIP-
ChIP with a Control siRNA was not conducted. We also observed a small subset of genes 
in the Mock transfected (transfection reagent alone) RNA-seq samples that had 
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drastically different FPKMs those of miR-191 or Control siRNA transfected samples 
(Figure 3.7). For this reason, we used the Control siRNA as our control when possible. 
 
 
Table 3.1 RNA-seq and microarray Spearman rank correlation. 
 
Figure 3.6 Example of RNA-seq and microarray correlation. 
miR-191 gene expression RNA-seq FPKM values compared to miR-191 microarray 
intensity values. Average of n = 3 for the RNA-seq and n = 2 for the micro array. 
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Figure 3.7 Comparing the Control siRNA to mock transfection in the gene expression 
experiments. 
(A) Control siRNA FPKMs compared to mock. (B) Control siRNA compared to miR-191 
FPKMs. (C) miR-191 compared to mock FPKMs. For A, B, and C, n = 3 for each 
condition, and FPKMs are the average of the 3 biological replicates. 
 
To determine if the RIP-Seq effectively identified miR-191 targets, we first 
examined the enrichment of mRNAs in the RIP-Seq compared to their levels of 
repressions in the gene expression experiments. RIP enrichment correlated well with 
repression of gene expression, and RIP enriched mRNAs were significantly more 
repressed than all genes profiled (Figure 3.8). In addition, RIP enriched mRNAs were 
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significantly more repressed in the gene expression experiments than all genes that 
contain the miR-191 7mer miRNA seed match in their 3’UTR, indicating the RIP more 
successfully identifies genes repressed by miR-191 transfection than using presence of 
the seed match as the lone criteria (Figure 3.9). RIP enrichment in combination with 
presence of the seed further increased mRNA repression (Figure 3.9). 
 
 
Figure 3.8 RIP enrichment correlates with repression of gene expression. 
Enrichment in the RIP was compared to levels of repression in the gene expression 
experiments. The Y-axis indicates the log2 of the enrichment in the RIP-Seq, and the X-
axis indicates the log2 of the gene expression repression value. Larger values indicate 
increased enrichment and increased repression. Pearson correlation= 0.78, n = 3. 
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Figure 3.9 mRNAs enriched in the RIP-seq also show reduced expression following 
miR-191 transfection. 
The Y-axis indicates the cumulative fraction of all mRNA transcripts profiled, and the X-
axis shows the level of repression for each mRNA transcript profiled. Black: all mRNAs 
profiled; Purple: all mRNAs profiled with a miR-191 7-mer miRNA seed match in their 
3’UTR; Red: all mRNAs 1.5 fold enriched in the RIP; Blue: all mRNAs 1.5 fold enriched 
in the RIP with a miR-191 7-mer miRNA seed match in their 3’UTR. mRNAs that 
contain a miR-191 miRNA 7mer seed match were significantly more repressed than all 
mRNAs profiled (p= 4.65e-24). mRNAs enriched in the RIP were significantly more 
repressed than mRNAs with a miR-191 7-mer seed match (p= 2.54e-12). mRNAs 
enriched in the RIP with a 7mer miR-191 seed match were significantly more repressed 
than mRNAs enriched in the RIP (p= 3.97e-17) Significance estimates were calculated 
with Student’s t-test. n = 3. 
 
As an additional means of determining RIP-seq effectiveness, we examined levels 
of enrichment for mRNAs that have a miR-191 seed match compared to all mRNAs 
profiled. mRNAs that contain a 7mer miR-191 seed match in their 3’UTR were 
significantly more enriched in the RIP than all mRNAs profiled (Figure 3.10). 
Conversely, mRNAs most enriched in the RIP had a high frequency of miR-191 seed 
sites in their 3’UTRs (Figure 3.11). Extending that analysis to the gene expression data, 
mRNAs that were most repressed following miR-191 transfection had the highest 
frequency of miR-191 seed sites (Figure 3.12). Using a combination of both RIP 
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enrichment and repression of gene expression to identify miRNA targets produced the 
highest frequency of seed sites in the most highly ranked targets (Figure 3.13). 
 
 
Figure 3.10 mRNAs with a miR-191 seed match were significantly enriched in the RIP-
seq. 
p= 4.65e-24, Student’s t-test. The Y-axis shows the cumulative fraction of all mRNA 
transcripts profiled, and the X-axis indicates the amount of enrichment in the RIP. Black: 
all mRNAs profiled; Red: mRNAs containing a 7-mer miR-191 seed match in their 
3’UTR; Blue: mRNAs with no 7-mer miR-191 seed match in their 3’UTR. n = 3 
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Figure 3.11 mRNAs enriched in the RIP-seq had the highest frequency of miR-191 seed 
matches. 
The X-axis denotes consecutive groups of 250 genes, ranked from most to least enriched 
in the RIP-seq. The line is the frequency indicated on the Y-axis of the miR-191 7-mer 
seed match in the 3’UTRs of the gene group relative to the frequency of the seed match 
in all mRNAs profiled. n = 3. 
 
Figure 3.12 mRNAs repressed in the gene expression experiments had the highest 
frequency of miR-191 7-mer seed matches. 
The X-axis indicates consecutive groups of 250 genes, ranked from most repressed to 
least repressed. The line is the frequency indicated on the Y-axis of miR-191 7-mer seed 
matches in the 3’UTRs of the gene group relative to the frequency of miR-191 seed 
matches in all mRNAs profiled. n = 3. 
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Figure 3.13 The highest ranked miR-191 targets had the highest frequency of miR-191 
seed matches. 
RIP-seq enrichment and gene expression repression data were combined to rank miR-191 
targets. The X-axis denotes consecutive groups of 250 genes, from most highly ranked to 
least highly ranked. The line is the frequency indicated on the Y-axis of miR-191 7-mer 
seed matches in the 3’UTRs of the gene group relative to the frequency of seed matches 
in all mRNAs profiled. Combined gene expression RNA-seq data, n = 3, with RIP-seq 
data, n = 3. 
3.4.3 mRNAs with miR-191 seed sites in the coding sequence display greater RISC 
occupancy and repression of gene expression than mRNAs with seed sites in the 
3’UTR 
miRNAs have traditionally been observed to post transcriptionally mediate gene 
expression by pairing to the 3’UTR of the target mRNA (24, 26). Extensive RISC 
binding to the CDS (coding sequence) region for a subset of miRNAs has been detected, 
but mediation of gene expression by CDS targeting was minor (27, 29, 30, 95, 96). This 
implies that although there is RISC occupancy of the CDS, functional targeting occurs 
through the 3’UTR. Due to a large fraction of miR-191 7mer seed matches being located 
in the CDS of protein coding genes, we hypothesized that miR-191 may mediate 
extensive RISC occupancy of the CDS, but exert a stronger influence on gene expression 
through 3’UTR pairing (Figure 3.14). In support of this hypothesis, we observed an 
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increase in the proportion of miR-191 target sites in the CDS of our experimentally 
identified miR-191 mRNA target set compared to all mRNAs profiled (64% compared to 
42%) (Figure 3.14). Our data also showed that mRNAs with a miR-191 target site in the 
CDS were significantly more enriched in the RIP than mRNAs with a miR-191 target site 
in the 5’UTR or 3’UTR (Figure 3.15). The group of mRNAs most enriched in the RIP-
seq do not show significant differences in enrichment between 5’UTR, CDS, or 3’UTR 
seed matches (Figure 3.15). Surprisingly, there is significantly stronger repression of 
gene expression when there is a CDS seed match present than one in the 3’UTR or 
5’UTR for both the RNA-seq and microarray experiments (Figure 3.16 and data not 
shown). In the group of most repressed mRNAs, we also see significantly stronger 
repression of gene expression when there is a CDS seed match compared to a 3’UTR 
seed match for both the RNA-seq and microarray data (Figure 3.16 and data not shown). 
Taken together, these results suggest that miR-191 may utilize extensive target pairing in 
the CDS, and exert a greater effect on gene expression through pairing to the CDS than 
the UTRs. 
 
Figure 3.14 RIP-seq enriched mRNAs have a higher proportion of miR-191 seed 
matches in the CDS than all mRNAs profiled. 
Left panel: All mRNAs profiled with a 7mer miR-191 seed match; Right panel: mRNAs 
1.5 fold enriched in the RIP-seq with a 7mer miR-191 seed match. The Y-axis indicates 
the number of genes, and the colors denote the number of genes with a seed match in the 
given location. n = 3. 
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Figure 3.15 RIP-seq enrichment depending on seed match location. 
mRNAs with a miR-191 seed match in the CDS were significantly more enriched in the 
RIP-seq than mRNAs with a miR-191 seed match in the 3’UTR or 5’UTR (p= 1.84e-06 
and p= 6.50e-05 respectively). Colors denote the seed match location. The cumulative 
fraction of all mRNAs profiled with the indicated seed match location is shown on the Y-
axis. The X-axis shows amount of enrichment in the RIP-seq. Solid lines are all mRNAs 
profiled with a miR-191 seed match, and dashed lines are the mRNAs 1.5 fold enriched 
in the RIP-seq with a seed match. P-values were estimated by Student’s t-test. n = 3. 
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Figure 3.16 Gene expression repression depending on seed match location. 
mRNAs with a miR-191 seed match in the CDS were significantly more repressed in the 
RNA-seq gene expression profiling than mRNAs with a seed match in the 3’UTR or 
5’UTR (p= 6.35e-10 and p= 8.87e-08, respectively). mRNAs with a miR-191 seed match 
in the CDS were significantly more repressed in the RNA-seq gene expression profiling 
than mRNAs with a seed match in the 3’ UTR (p= 1.17e-05). Colors denote the seed 
match location. The cumulative fraction of all mRNAs profiled with the indicated seed 
match location is shown on the Y-axis. The X-axis shows amount of repression measured 
by RNA-seq. Solid lines are all mRNAs profiled with a miR-191 seed match, and dashed 
lines are the mRNAs 1.5 fold repressed in the miR-191 RNA-seq with a seed match. P-
values were estimated by Student’s t-test. n = 3. 
3.4.4 miR-191 directly targets multiple proto-oncogenes 
In our experimentally identified set of miR-191 targets, there was strong 
enrichment for genes associated with cell proliferation, cell division, the MAPK signaling 
pathway, and cancer pathways (Figure 3.17 & Appendix 1). We selected multiple proto-
oncogenes and regulators of proliferation to further investigate as miR-191 targets. To 
confirm direct miR-191 targeting of the genes, we cloned ~0.5 - 1kb sections of the 
3’UTRs into luciferase reporter constructs. CDK6 was one of our putative targets and had 
previously been identified as a direct target of miR-191 by multiple groups (87, 88, 97). 
The luciferase reporter assays confirmed 7 of the 8 putative targets as direct targets of 
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miR-191, and deletions of the miR-191 seed matches showed that the miR-191 mediated 
repression of the 3’UTRs in the assay was dependent on the miR-191 seed matches in the 
3’UTRs (Figure 3.18). To further confirm these genes as direct targets and examine the 
effect of miR-191 on the expression of these genes in primary human fibroblasts, we 
transfected mature miR-191 duplexes into primary fibroblasts and assayed transcript and 
protein levels. miR-191 transfection in fibroblasts significantly repressed the transcript 
levels of AGO2, BCL2, CDK6, CDK9, NOTCH2, and RPS6KA3, but not PRMT or 
SLC7A1 (p= 0.11 and p= 0.08) (Figure 3.19). Western blotting for a subset of the genes 
following miR-191 transfection in fibroblasts and HeLas confirmed miR-191 repression 
of CDK9, NOTCH2, and RPS6KA3, Ago2 only showed repression in HeLas (Figure 
3.20 and data not shown). This discrepancy may be due to differences in protein stability 
in combination with the transient nature of the transfections. 
 
 
Figure 3.17 Enriched Gene Ontology terms and KEGG Pathways for the experimentally 
identified set of miR-191 targets. 
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Figure 3.18 Direct targets of miR-191. 
Luciferase reporter assays show miR-191 directly targets the 3’UTRs of the genes 
indicated on the X-axis. The Y-axis denotes relative luciferase units from miR-191 
transfected HEK293 cells normalized to Control siRNA transfected cells. Red bars: 
3’UTRs with the putative miR-191 target site entirely deleted. Blue bars: Intact 3’UTRs. 
Error bars denote ± SD, n = 6. Bars indicate the mean. P-values were estimated by 
Students one tailed paired t-test comparing intact 3’UTR samples to mutant 3’UTR 
samples. *P < 0.05. 
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Figure 3.19 miR-191 transfection significantly decreased AGO2, BCL2, CDK6, CDK9, 
NOTCH2, and RPS6KA3 transcript levels in fibroblasts. 
Fold changes are indicated on the Y-axis relative to the Control siRNA transfection. 
GAPDH was used to normalize input RNA levels. Bars indicate the mean, and error bars 
denote ± SD, n = 3. P-values were estimated by Student’s one tailed t-test. *P < 0.05. 
 
Figure 3.20 miR-191 transfection in fibroblasts decreased protein expression of CDK9, 
NOTCH2, and RPS6KA3. 
Compared to Control siRNA transfection. Band intensities were quantified, normalized to 
GAPDH, and shown relative to the Control siRNA.  
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3.4.5 The involvement of miR-191 in NSCLC  
miR-191 has previously been shown to repress or enhance proliferation in a 
cancer type and cancer subtype dependent manner (83, 84, 87). Despite the involvement 
of miR-191 in a plethora of different cancer types, miR-191 was shown to have to no 
effect on proliferation in lung cancer in the small cell lung cancer (SCLC) cell line A549 
(98). We used the MIRUMIR tool to query the prognostic value of miR-191 in multiple 
cancer types, and observed the highest correlation between NSCLC and miR-191 
expression (93). Patients with high miR-191 expression have a significantly lower 
survival probability than patients with low miR-191 expression (Figure 3.21). Transient 
overexpression of miR-191 in multiple NSCLC derived cell lines showed a cell type 
dependent effect on proliferation (Figure 3.22A). The effect on cell cycle progression 
following miR-191 transfection correlated with the effect of miR-191 on proliferation 
marker Ki67 in H2444 NSCLC cells, but not H460 cells or H2122 cells (Figure 3.22A & 
B). Although proliferation in H460 cells was significantly repressed, there was no change 
in cell cycle progression suggesting miR-191 has little effect on proliferation in H460s. 
There was a consistent and significant increase in cell cycle progression in H2122 cells 
following miR-191 transfection, but no change in the fraction of the cell population 
expressing Ki67. This may be due to a large fraction of the cancer cell population already 
existing in a proliferative state and expressing high levels of Ki67. In total, this data 
shows miR-191 has no overall consistent effect on NSCLC proliferation and suggests 
miR-191 may effect NSCLC progression in a cancer subtype dependent manner.  
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Figure 3.21 High miR-191 expression correlates with a lower survival probability in 
NSCLC cancer patients. 
p= 4.27e-03. Kaplan-Meier survival curves for patients with NSCLC cancer with 
different levels of miR-191 expression were calculated using the MIRUMIR tool. 
 
 
Figure 3.22 miR-191 transfection regulates NSCLC cell proliferation in a cell type 
specific manner. 
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Figure 3.22 miR-191 transfection regulates NSCLC cell proliferation in a cell type 
specific manner. 
(A) Shown by flow cytometry analysis for expression of proliferation marker Ki67 in 
miR-191 transfected NSCLC cell lines. The Y-axis indicates the relative percentage of 
cells expressing Ki67. Bars are the mean percentage of cells expressing Ki67 relative to 
the Control siRNA. (B) miR-191 transfection alters cell cycle progression of NSCLC cell 
lines in a cell line dependent manner. Shown by flow cytometry analysis of cell cycle 
progression using propidium iodide staining of miR-191 transfected NSCLC cell lines. 
The Y-axis denotes the percentage of cells found in each stage of the cell cycle, and bars 
are the mean percentage the cell population found in each stage. For A and B, error bars 
indicate ± SD, n = 6. P-values were estimated by Student’s t-test. *P < 0.05. 
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3.5 DISCUSSION 
In this study, we showed that miR-191 regulates proliferation in multiple cell 
types and targets a number of proto-oncogenes. By constructing a transcriptome wide 
miR-191 target set, we were able to identify and confirm the regulators of proliferation 
CDK9, NOTCH2, and RPS6KA3 as direct targets of miR-191. We demonstrated that 
miR-191 represses proliferation and cell cycle progression in primary human fibroblasts. 
In addition, our results suggested that miR-191 mediates gene expression of a large 
proportion of its target genes by binding to the CDS. Finally, we explored the role of 
miR-191 in NSCLC proliferation, and observed cell line specific regulation by miR-191. 
CDK9 regulates RNA polymerase II controlled gene expression to mediate cell 
growth, proliferation, apoptosis and differentiation (99). CDK9 activity is deregulated in 
numerous malignancies and human pathologies, and is a target for pharmacological 
inhibition for cancer therapies (99). NOTCH2 is overexpressed in multiple cancer types 
and has been shown to have oncogenic effects, including on proliferation (100, 101). 
RPKS6KA3 is part of the MAPK3 pathway, and promotes proliferation in multiple 
cancer types (102, 103). Although the effect of miR-191 on the protein levels of CDK9, 
NOTCH2, and RPS6KA3 was modest, moderate repression of multiple key proliferation 
associated genes may have large phenotypic effects in concert.  
miR-191 expression is frequently altered in tumors, and may be up or down 
regulated depending on cancer type (97). miR-191 has predominately been shown to act 
as an oncogene, promoting tumorigenesis in gastric, colorectal, breast, thyroid, and 
hepatocellular carcinoma, but has also been shown to inhibit tumorigenesis in thyroid 
carcinoma and breast cancer (83, 85, 87, 97). In multiple cases, miR-191 influences 
tumor progression by regulating proliferation; miR-191 promotes proliferation in 
hepatocellular carcinoma, and in gastric carcinoma by targeting NDST1, but inhibits 
proliferation in thyroid carcinoma by targeting CDK6 (83, 84). The duality of miR-191 is 
illustrated in breast cancer: miR-191 impairs or promotes breast cancer tumorigenesis 
depending on ER-alpha receptor status (87, 104). We examined the effect of miR-191 on 
proliferation of multiple NSCLC cell lines, and observed a cell line dependent effect on 
proliferation despite the significant correlation of high miR-191 expression with low 
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survival probability in NSCLC. Interestingly, in a different lung cancer subtype, SCLC, 
miR-191 had no effect on proliferation (98). Taken as a whole, the cancer, cancer 
subtype, and cell line specific effects of miR-191 on proliferation suggest miR-191 
regulates proliferation in a manner dependent upon cancer subtype and genetic context. 
Transcriptome wide gene expression analysis following miRNA perturbation has 
shown that miRNA seed matches in the CDS have little effect on transcript levels (24, 
26). Transcriptome wide profiling of miRNA targets using more recently developed 
biochemical techniques has revealed extensive RISC occupancy of the CDS, but the 
effect on transcript levels by CDS targeting was generally negligible (27, 29, 30, 95, 96). 
At most, target sites in the CDS exert about half as strong of an effect on transcript levels 
as targets in the 3’UTR (27). We observed a large fraction of miR-191 seed matches in 
the CDS, and in agreement with previous studies extensive miR-191 dependent RISC 
occupancy of the CDS. However, we also showed extensive miR-191 dependent 
regulation of transcript levels for mRNAs with a miR-191 seed match in the CDS, and 
the mRNAs with a seed match in their CDS showed a significantly stronger response than 
those with a 3’UTR seed match. The regulatory effect exerted by miR-191 through CDS 
binding may be an isolated case, but it raises the intriguing possibility that other miRNAs 
may employ CDS binding to regulate gene expression.  
In summary, we demonstrated that miR-191 represses proliferation of primary 
human cells, and exerts a cell type dependent effect on NSCLC proliferation. We also 
showed that miR-191 targets and represses expression through binding to the CDS. 
Finally, we constructed a transcriptome wide profile of miR-191 targets and confirmed 
multiple novel proto-oncogene targets of miR-191. 
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Chapter 4 miR-503 represses human cell proliferation and directly 
targets the oncogene DDHD2 by non-canonical target pairing. 
4.1 ABSTRACT 
The pathways regulating the transition of mammalian cells from quiescence to 
proliferation are mediated by multiple miRNAs. Our understanding of miRNA targeting 
has significantly improved, but the majority of miRNA regulatory networks are still 
largely unknown and require experimental validation. Here we show that miR-503, miR-
103, and miR-494 promote proliferation in primary human cells. We experimentally 
identified their targets using RNA-induced silencing complex immunoprecipitations 
(RIPs) and gene expression profiling. Through analysis of the transcriptome wide target 
profiles, we observed evidence of non-canonical target pairing by the miRNAs. We 
identified the oncogene DDHD2 as a target of miR-503 that requires pairing outside of 
the canonical 5’ seed region of miR-503. Further bioinformatics analysis implicated miR-
503 and DDHD2 in breast cancer tumorigenesis. Our results provide an extensive 
transcriptome wide set of targets for miR-503, miR-103, and miR-494, and suggest the 
involvement of miR-503 in breast cancer by its direct non-canonical targeting of 
DDHD2. 
4.2 INTRODUCTION 
 miRNAs were initially observed to predominantly target and direct the RNA-
induced silencing complex (RISC) to mRNAs through perfect pairing of the seed region 
located at the 5’ end of the miRNA (23, 24, 26). There are known examples of miRNAs 
that utilize further pairing to either complement pairing at the 5’ seed, or compensate for 
mismatches in pairing at the 5’ seed, but until recently, miRNAs were thought to rarely 
employ non-canonical targeting (105). Recent improvements in methodologies to 
globally identify miRNA targets revealed more widespread use of alternative targeting by 
miRNAs (27-30). In one case, Loeb et al. noted approximately 40% of miR-155 
dependent binding of RISC occurred at sites without perfect seed pairing (29). Most 
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recently, Helwark et al. observed 60% of all miRNA target pairs displayed bulges or 
mismatches in the seed region (27). 
 miR-503, miR-103, and miR-494 have previously been shown to act as either 
oncogenes or tumor suppressors in different cellular contexts (106-110). miR-503 acts as 
a tumor suppressor in non-small cell lung cancer, glioblastoma, and hepatocellular 
carcinoma (110-114). Despite the broad involvement of miR-503 in repressing 
tumorigenesis in various cancers, the function of miR-503 has not been explored in either 
primary cells or breast cancer. 
 In this study, we investigated the regulation of cell proliferation in primary human 
cells by miR-503, miR-103, and miR-494. We identified a transcriptome wide set of the 
targets of miR-503, -103, and -494 by conducting extensive profiling of RISC associated 
transcripts and gene expression profiling. Computational analysis of the globally 
identified targets indicated utilization of non-canonical target pairing for miR-503 and -
103. We further explored the targeting mechanisms of miR-503 experimentally, and 
confirmed that miR-503 targets the oncogene DDHD2 through non-canonical target 
pairing. Additional bioinformatic analysis showed a link between miR-503, DDHD2, and 
breast cancer.  
4.3 MATERIALS AND METHODS 
Methods used were the same as those in described in Chapter 3 unless otherwise noted. 
4.3.1 Defining a miRNA target list using RIP enrichment and gene expression 
repression 
 Target scores to rank each mRNA were generated by averaging RIP enrichment 
values and gene expression repression values. mRNAs with a score of 1.75 or greater 
were designated as the target set.  
4.3.2 Searching for non-canonical target pairing 
 For miR-503, the criteria used to search for compensatory sites (5’ mismatch + 
additional 3’ pairing) were: (1) a 6-mer matching position 1-6 with 1 mismatch, and (2) 
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an 8-mer matching position 11-18 with 0 – 3 mismatches, (3) a 1 base pair wobble 
allowed in the length of the sequence separating the 6-mer and 8-mer. To search for 
complementary sites (5’ mismatch + additional 3’ pairing) the criteria used were: (1) a 6-
mer perfectly matching position 1-6, and (2) an 8-mer matching position 11-18 with 0 – 3 
mismatches, (3) a 1 base pair wobble allowed in the length of the sequence separating the 
6-mer and 8-mer. 
For miR-103, the criteria used to search for compensatory sites (5’ mismatch + 
additional 3’ pairing) were: (1) a 6-mer matching position 2-7 with 1 mismatch, and (2) 
an 8-mer matching position 11-18 with 0 – 3 mismatches, (3) a 1 base pair wobble 
allowed in the length of the sequence separating the 6-mer and 8-mer. To search for 
complementary sites (5’ mismatch + additional 3’ pairing) the criteria used were: (1) a 6-
mer perfectly matching position 2-7, and (2) an 8-mer matching position 13-20 with 0 – 3 
mismatches, (3) a 1 base pair wobble allowed in the length of the sequence separating the 
6-mer and 8-mer. 
4.3.3 Luciferase reporter assays 
We cloned 0.9 kb of the 3’UTR of DDHD2 centered around the putative miR-503 
binding site into the psi-CHECK2 plasmid (Promega) downstream from the Renilla 
luciferase gene using XhoI and NotI restriction sites. This plasmid was used to produce 
three mutant variants. In the whole-site deletion variant, the entire 22 bp sequencing 
corresponding to the length of miR-503 at its binding site was deleted. In the 3’ deletion 
variant, the 6 bp sequence corresponding to positions 7-12 of the putative binding site 
(Figure 4.16) (and positions 11-16 of the miRNA in a putative duplex) was deleted. In the 
5’ deletion variant, the 6 bp sequence corresponding to positions 17-22 of the putative 
binding site (Figure 4.16) (and positions 2-7 of the miRNA in a putative duplex) was 
deleted. 
HEK293 cells were plated in 24-well plates at 105 cells/well in DMEM 
supplemented with 10% FBS and 1% Pen-Strep and grown overnight (Hyclone, Gibco). 
Each plasmid was co-transfected at 50 ng/well with either miRNA or siGFP duplex at a 
100 nM in triplicate (Lipofectamine, Invitrogen). Cells were harvested 24 hours post-
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transfection and luciferase activity was measured using the Promega Dual Luciferase kit 
according to manufacturer’s instructions. Data was first normalized per-well by dividing 
Renilla luminescence by Firefly luminescence. Then, the mean of the three biological 
replicates for each miRNA transfected group was divided by the mean of its 
corresponding siGFP transfected group to determine the relative luciferase activity value. 
4.3.4 Western blotting 
Primary human fibroblasts or HeLa cells were seeded in 6-well plates at 5 x 104 
cells/well in DMEM supplemented with 10% FBS (Hyclone, Invitrogen). 24 hours after 
plating, miR-503 or siGFP duplexes were transfected at a 100 nM concentration 
(Lipofectamine, Invitrogen). Transfected cells were lysed at 24 hr, 48 hr, 72 hr, or 96 hr 
post-transfection. 
Cell lysates were separated on 4-20% gradient SDS-PAGE gels (Biorad) and 
proteins were transferred onto PVDF membranes. Membranes were blocked with 5% 
milk or 5% BSA in TBST and probed overnight with primary antibody in blocking 
solution (DDHD2: 1/500, Abacam, ab103965 ; GAPDH: 1/1000, Abcam, ab9486). The 
membranes were washed, incubated with HRP-conjugated secondary antibody in 
blocking solution (1/5000, Santa Cruz Biotechnology, sc-2004), and washed again. HRP 
substrate solution was added to the membranes, and incubated for four minutes (Pierce). 
Blots were exposed to autoradiographic film and developed (Carestream Kodak Biomax). 
Images of the films were scanned and band intensities quantified using a white-light 
transilluminator imaging system (FlourChem Q, ProteinSimple). 
4.3.5 Cancer survival and copy number alteration analysis 
Survival probabilities of ER+ breast cancer patients were generated with 
MIRUMIR (http://www.bioprofiling.de/GEO/MIRUMIR/mirumir.html) (93). Data on 
DDHD2 copy number alteration frequency and patient survival in patients with different 
cancer types was generated using cBio portal (http://www.cbioportal.org/public-
portal/)(115). For each cancer type the percentage of patients with DDHD2 
amplifications, and patient survival probabilities, were calculated as an average of all data 
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sets available for this cancer type. P-values were calculated with a hypergeometric 
distribution. 
4.4 RESULTS 
4.4.1 miR-503, miR-103, and miR-494 repress proliferation 
miRNAs that regulate proliferation are differentially expressed in quiescent and 
proliferating primary human fibroblasts (116). Using previously published data as well as 
additional miRNA expression profiling of primary human fibroblasts transitioning from 
quiescence to proliferation, we identified numerous miRNAs induced in fibroblasts 
transitioning from quiescence to proliferation (116). Multiple miRNAs were selected for 
further study based on two criteria: (1) Consistent induction by serum stimulation, and (2) 
bioinformatic analysis indicating that the miRNA targets proliferation and or cell cycle 
related genes (data not shown). 
As a preliminary screen to identify miRNAs that regulate proliferation, we 
transiently overexpressed each miRNA by transfecting the mature duplex form of the 
miRNA into proliferating fibroblasts and assayed cell proliferation by expression of the 
proliferation marker Ki67 (53, 54). Surprisingly, multiple miRNAs appeared to decrease 
Ki67 levels, although this decrease was not statistically significant (Figure 4.1). miRNAs 
induced by serum stimulation were expected to increase proliferation, but there are 
numerous examples of miRNAs that participate in negative feedback loops (116-118). Of 
the miRNAs assayed, miR-503, miR-103, and miR-494 displayed the greatest reduction 
in Ki67 levels and were selected for further study (Figure 4.1). 
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Figure 4.1 Screening for miRNA regulation of proliferation. 
Proliferation of primary fibroblasts as measured by Ki67 expression levels. miRNA or 
Control siRNA duplexes were transfected into normally growing fibroblasts, and Ki67 
levels of the cell population were measured by qRT-PCR. The column graph shows Ki67 
expression levels relative to the control, which was set to a value of 1.0. Bars indicate the 
mean, and error bars denote ± s.d., n=3. P-values were estimated by Student’s paired t-
test. *, P<0.05. 
 
To more thoroughly investigate the effect of miR-503, miR-103, and miR-494 on 
cell proliferation, we transiently overexpressed each of these miRNAs in proliferating 
fibroblasts and assayed the rate of cell growth. miR-503, -103, and -494 transfected cells 
showed significant reductions in the rate of cell growth (Figure 4.2). To confirm their 
effect on cell growth, we transfected miR-503, -103, -494, and miR-34a, a well known 
tumor suppressor (94), into proliferating fibroblasts and counted cells expressing Ki67 
protein using flow cytometry. miR-503, -103, and -494 transfection significantly 
decreased the percentage of Ki67 positive cells compared to multiple controls, indicating 
that these three miRNAs repress proliferation, although not to the extent of miR-34a 
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(Figure 4.3). In addition, transient overexpression of miR-503, -103, and -494 in 
proliferating fibroblasts significantly decreased the rate of progression through the cell 
cycle (Figure 4.4).  To rule out indirect effects from flooding the cells and the RNA 
silencing machinery with large amounts of the mature miRNA duplexes, we transiently 
inhibited miR-503, -103, and -494 in fibroblasts induced into quiescence by serum 
removal. Inhibition of miR-503, -103, and -494 in quiescent fibroblasts significantly 
increased the rate of cell growth (Figure 4.5). 
 
Figure 4.2 miR-503, -103, and -494 transfection reduces cell growth. 
Average cell number relative to 0hr following miRNA or Control siRNA transfection is 
shown for each time point indicated in primary human fibroblasts. Error bars denote ± 
SD, n = 6. P-values were estimated by Student’s t-test. 
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Figure 4.3 miR-503 and -494 transfection represses proliferation. 
Shown by flow cytometry analysis for proliferation marker Ki67 of miR-503, -103, or -
494 transfected fibroblasts. The Y-axis indicates the relative percentage of cells 
expressing Ki67. Bars are the mean percentage of cells expressing Ki67 relative to 
Control RNA 2, and error bars denote ± SD, n = 3. P-values were estimated by Student’s 
t-test. 
 
 
Figure 4.4 miR-503, -103, and -494 transfection inhibits progression through the cell 
cycle. 
Shown by flow cytometry analysis of cell cycle progression using propidium iodide 
staining of miR-503, -103, or -494 transfected fibroblasts. The Y-axis indicates the 
percentage of cells found in each stage of the cell cycle, and bars are the mean percentage 
the cell population found in each stage. Error bars denote ± SD, n = 3. P-values were 
estimated by Student’s paired t-test. *P < 0.05. 
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Figure 4.5 Inhibition of miR-503, -103, and -494 increases cell growth in fibroblasts 
serum starved into quiescence. 
Average cell number relative to 0hr following transfection of an LNA targeting miR-503, 
-103, or -494 or a LNA negative control is shown for each time point indicated. Error 
bars denote ± SD, n = 6. P-values were estimated by Student’s t-test. *P < 0.05. 
4.4.2 Transcriptome wide identification of miR-503, -103, and -494 targets 
 To experimentally identify the targets of miR-503, -103, and -494 we used two 
approaches: (1) profiling of transcripts isolated from RIPs after transient overexpression 
of miR-503, -103, and -494, and (2) profiling gene expression after transient 
overexpression of the miRNAs (Figure 3.5). To immunoprecipitate RISC, we used a 
monoclonal antibody directed against Argonaute-2, an essential component of RISC (23). 
RISC is directed to target mRNAs by the mature miRNA guide strand (23). Increases in 
RISC occupancy on a given transcript following miRNA overexpression indicate direct 
targets of the overexpressed miRNA. We globally profiled RISC occupancy by 
quantifying transcripts isolated from RIPs using both microarrays (RIP-ChIP) and RNA-
seq (RIP-Seq). As described for miR-191, enrichment was defined as an increase in RISC 
occupancy on a given transcript following miRNA transfection compared to the control 
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transfection. To obtain enough RNA for successful global profiling, all RIPs and gene 
expression experiments were conducted in HeLa cells, due to HeLa cells having a greater 
RNA content and being of a smaller size than human fibroblasts. As with miR-191, we 
observed strong correlation between the RNA-Seq and microarray experiments (Table 
4.1). As previously stated, No RIP Control siRNA comparison could be made because 
RIP-ChIP with a Control siRNA was not conducted. 
 
Table 4.1 RNA-seq and microarray Spearman rank correlation. 
 To determine if the RIP-Seq effectively identified miRNA targets, we first 
examined the enrichment of mRNAs in the RIP-Seq compared to their levels of 
repression in the gene expression experiments. Enrichment in the RIP-Seq correlated well 
with repression of gene expression (Table 4.2). mRNAs enriched in the RIPs for miR-
503, -103, and -494 were significantly more repressed than all mRNAs profiled (Figure 
4.6). In addition, mRNAs enriched in the RIPs for miR-503, -103, and -494 were 
significantly more repressed than all genes that contain the respective 7mer miRNA seed 
match in their 3’UTR, indicating the RIPs more successfully identified genes repressed 
by the miRNAs than using presence of the seed match as the lone criteria to identify 
miRNA targets (Figure 4.6). 
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Table 4.2 RIP enrichment correlates with repression of gene expression. 
Enrichment in the RIP was compared to levels of repression in the gene expression 
experiments. Pearson correlation, n = 3. 
 
 
 
 
 
 
 
 
 
 
 
 83 
 
Figure 4.6 mRNAs enriched in the RIP-seq also showed reduced expression following 
miR-503, miR-103, or -494 transfection. 
The Y-axis denotes the cumulative fraction of all mRNA transcripts profiled, and the X-
axis indicates the level of repression for each mRNA transcript profiled. Black: all 
mRNAs profiled; Red: all mRNAs profiled that contain the respective 7-mer miRNA 
seed site in their 3’UTR; Purple: all mRNAs 1.75 fold enriched in the RIP; Blue: all 
mRNAs 1.75 enriched in the RIP that contain the respective 7-mer miRNA seed site in 
their 3’UTR. mRNAs that contain the respective miRNA 7-mer seed were significantly 
more repressed than all mRNAs profiled for miR-103, and -494, but not -503 (p= 1.16e-
4, 3.17e-36, and 0.09, respectively). mRNAs enriched in the RIPs were significantly 
more repressed than mRNAs containing the respective miRNA seed for miR-503, -103, 
and -494 (p= 2.95e-40, 4.69e-13, and 1.82e-81, respectively). mRNAs enriched in the 
RIP and containing the 7-mer miRNA seed were significantly more repressed than 
mRNAs enriched in the RIP for miR-494, but not miR-503 or -103 (p= 2.77e-08, 0.79, 
and 0.31, respectively) Significance estimates were calculated with Student’s t-test. n = 3. 
 
As a second measure of RIP-seq effectiveness, we examined miRNA seed site 
frequency in RIP enriched mRNAs. mRNAs most enriched in the miR-503, -103, and -
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494 RIPs had a high frequency of their corresponding miRNA seed sites (Figure 4.7). 
Conversely in the gene expression data, mRNAs that were most repressed following 
miRNA transient over expression showed the greatest enrichment for miR-503, -103, and 
-494 seed sites (Figure 4.8). Using a combination of both RIP enrichment data and 
repression of gene expression data to identify miRNA targets produced the highest 
frequency of seed sites in the most highly ranked targets (Figure 4.9). In addition, there 
was enrichment for proliferation related genes in the targets identified for miR-503 and 
miR-494, but there were not enough target genes identified for miR-103 to produce 
meaningful results (Appendix 1) (90-92).  
 
Figure 4.7 mRNAs enriched in the RIPs had the highest frequency of the respective 
miRNA seed site. 
The X-axis denotes consecutive groups of 250 genes, ranked from most enriched to least 
enriched in the RIP-seq. The line is the frequency indicated on the Y-axis of the 
respective 7-mer miRNA seed in the gene group relative to the frequency of the seed in 
all genes profiled. n = 3. 
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Figure 4.8 miR-103, and -494, mRNAs repressed in the gene expression experiments 
had the highest frequency of the respective miRNA seed. 
The X-axis indicates consecutive groups of 250 genes, ranked from most repressed to 
least repressed. The line is the frequency indicated on the Y-axis of the respective 7-mer 
miRNA seed in the gene group relative to the frequency of the seed in all genes profiled. 
n = 3. 
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Figure 4.9 The highest ranked miRNA targets had the highest frequency of the 
respective miRNA seed sites. 
RIP enrichment and gene expression repression data were combined to rank miRNA 
targets. The X-axis denotes consecutive groups of 250 genes, from most highly ranked to 
least highly ranked. The line is the frequency indicated on the Y-axis of the respective 7-
mer miRNA seed in the gene group compared to the frequency of the seed in all genes 
profiled. Combines gene expression data, n = 3, with RIP-seq data, n = 3.  
4.4.3 Enrichment of sequences pairing to the 3’ end of the miRNAs in the 
experimentally profiled miRNA targetome 
 
To determine the sub-sequences of miR-503, -103, and -494 that are used for 
targeting, we examined enrichment of 6-mer sequences that pair different areas of the 
mature miRNAs in the 3’UTRs of the experimentally identified target gene sets (Figure 
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4.10). As expected, there was a high frequency of 6-mer sequences that pair to the seed 
region, positions 2-7, of the mature miRNAs (Figure 4.10). Surprisingly, there was also a 
high frequency of sequences that pair the 3’ end of the mature miRNAs. We observed the 
same phenomenon in targets identified by the separately conducted RIP-Chip and 
microarray gene expression profiling experiments (data not shown). Nelson et al. had 
previously reported this same finding when conducting global target identification for 
miR-103, and concluded that miR-103 utilized 3’ pairing for targeting, although they did 
not further explore this observation experimentally (119). Based on the enrichment for 
the 5’ seed site and a distinct 3’ site for miR-503 and miR-103, as well as the observed 
miR-103 3’ enrichment by Nelson et al., we hypothesized that miR-503 and -103 were 
using complementary or compensatory pairing to target mRNAs. Complementary pairing 
employs a perfect 5’ seed match with additional 3’ pairing, and compensatory pairing 
uses additional 3’ pairing to compensate for mismatches or bulges in the 5’ seed site 
(Figure 4.11)(23). Although miR-494 targets also displayed extensive enrichment for 6-
mers pairing outside of the 5’ seed region, the areas of enrichment were more diffuse, 
making them more difficult to investigate experimentally (Figure 4.10). 
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Figure 4.10 Enrichment of sequences pairing to the 3’ end of the miRNAs in the 
experimentally determined miRNA targetomes. 
Shown by the frequency of 6-mer sequences pairing to each 6-mer sequence in the 
mature miRNAs. Bars are the frequency indicated on the Y-axis of a 6-mer in the 
globally identified targets relative to all mRNAs profiled. 6-mers are organized along the 
X-axis from 5’ end to 3’ end of the mature miRNA. 
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Figure 4.11 Different types of miRNA-target pairing. 
To investigate the type of target pairing used by miR-503 and -103, we began by 
further analyzing our RIP-seq data and RNA-seq gene expression data. We first 
examined the frequency of compensatory and complementary pairing sites in highly 
ranked targets. Due to the most enriched 5’ 6-mer for miR-503 being from position 1-6 
(Figure 4.10), for miR-503 we used both a canonical 5’ position 2-7 seed site, as well as a 
5’ position 1-6 seed site. The frequency of compensatory pairing sites in the target gene 
set for either miR-503 or miR-103 was not higher than the frequency of 5’ seed sites 
(Figure 4.12). However, complementary pairing sites were much more frequent than the 
5’ seed sites and compensatory pairing sites (Figure 4.12). 
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Figure 4.12 Frequency of different types of miRNA pairing sites in RIP-Seq enriched 
mRNAs. 
Bars are the frequency of mRNAs with the indicated type of miRNA pairing site in the 
RIP enriched mRNAs, relative to the frequency of mRNAs with the indicated type of 
miRNA pairing site in all mRNAs profiled.  
 
Next we examined RIP-seq enrichment and repression of mRNA targets with 
compensatory or complementary pairing sites. mRNAs that were enriched in the RIP for 
miR-503 and contained complementary pairing sites were significantly more repressed 
than all mRNAs that were enriched in the RIP (Figure 4.13A). In agreement with the 
RIP-Seq, the RIP-ChIP showed a significant but minor increase in repression for 
complementary pairing sites (data not shown). There were no significant differences in 
repression for miR-103 or in enrichment for either miR-503 or miR-103 depending on 
pairing type (Figure 4.13B and data not shown). When we expanded our analysis to 
include all genes profiled, we observed no significant differences in enrichment or 
repression between genes with a 5’ seed site, a compensatory pairing site, or a 
complementary pairing site (data not shown). Taken together, this data strongly suggests 
miR-503 may utilize complementary target pairing. There were no differences between 
compensatory target pairing sites and the intact 5’ seed alone for both miR-503 and miR-
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103, making it difficult to draw conclusions as to utilization of compensatory target 
pairing. 
 
 
Figure 4.13 Repression of mRNAs with a complementary pairing site. 
(A) RIP-seq enriched mRNAs containing a complementary pairing site in their 3’UTR 
are significantly more repressed than all RIP-seq enriched mRNAs, but not all RIP-seq 
enriched mRNAs that contain a perfect 5’ seed in their 3’UTR (p= 0.04 and 0.06, 
respectively, Student’s t-test). Shown by comparing repression of gene expression in 
miR-503 RIP enriched mRNAs with different types of miRNA-target pairing site. Each 
box and whiskers indicates gene expression repression for genes that contain the type of 
miRNA-target pairing site specified on the X-axis. Boxes extend from the 1st to 3rd 
quartile of gene expression repression, the band is the median, and whiskers denote the 
min and max excluding outliers. (B) There were no significant differences in miR-503 
RIP enrichment of gene expression in RIP enriched mRNAs with different types of 
miRNA-target pairing site. Each box and whiskers indicates RIP enrichment for mRNAs 
that contain the type of miRNA pairing site specified on the X-axis. Boxes extend from 
the 1st to 3rd quartile of RIP enrichment, the band is the median, and whiskers denote the 
min and max excluding outliers. 
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4.4.4 Pairing of the 3’ and 5’ end of miR-503 is necessary for direct targeting by 
miR-503 of the cell growth promoting gene DDHD2 
 To experimentally determine the target pairing mechanisms used by miR-503 we 
cloned the 3’UTRs of multiple genes with pairing to the 5’ and 3’ end of miR-503 into 
luciferase reporter constructs. The genes were selected based on three criteria: (1) 
combined RIP-seq and RNA-seq gene expression repression rank, (2) sequences in their 
3’ UTR that paired the 5’ and 3’ end of miR-503, and (3) their involvement in promoting 
cell proliferation (Figure 4.14). For controls, we deleted the putative miR-503 target 
pairing sites in the 3’UTRs of the selected genes. Surprisingly, miR-503 repressed none 
of the reporters compared to controls with 3’ UTRs from genes with sites with a 
mismatch in the 5’ seed region and additional 3’ pairing (Figure 4.15). miR-503 did 
repress expression of the reporter with the 3’UTR of DDHD2 that has a perfect miR-503 
5’ seed match and additional 3’ pairing (Figure 4.15), indicating that miR-503 utilizes 
complementary but not compensatory target pairing. To determine the involvement of 
miR-503 5’ and 3’ pairing in targeting DDHD2, we constructed additional reporter 
constructs of the 3’UTR of DDHD2 with the sequence matching the 5’ end of miR-503 
deleted or the sequence matching the 3’ end of miR-503 deleted (Figure 4.16). 
Unexpectedly, leaving 5’ pairing intact and deleting only the sequence pairing the 3’ end 
of miR-503 significantly relieved repression by miR-503, indicating miR-503 requires 3’ 
pairing to target DDHD2 in addition to the 5’ perfect seed match (Figure 4.16). As 
expected, deleting the sequence matching the 5’ seed of miR-503 also significantly 
relieved repression (Figure 4.16). Interestingly, the difference was not significant in 
luciferase reporter activity between the 3’ and 5’ deletion constructs.  To further confirm 
functional targeting of DDHD2 by miR-503, we transfected miR-503 into proliferating 
fibroblasts and HeLas. Transient overexpression of miR-503 did not repress the transcript 
levels of DDHD2 in proliferating primary human fibroblasts (data not shown) but did 
decrease protein levels in both fibroblasts and HeLas, indicating miR-503 more strongly 
represses DDHD2 expression through inhibition of translation than mRNA 
destabilization (Figure 4.17).  
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Figure 4.14 Diagram of miR-503 non-canonical target pairing sites in the 3’ UTRs of 
putative targets. 
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Figure 4.15 Luciferase reporter assays investigating non-canonical miR-503 target 
pairing. 
The 3’UTRs of mRNAs being investigated are indicated on the X-axis. The Y-axis 
denotes relative luciferase units from miR-503 transfected cells normalized to Control 
siRNA transfected cells. Red bars: 3’UTRs with the putative miR-503 target site entirely 
deleted. Blue bars: Intact 3’UTRs. Error bars denote ± SD, n = 3. P-values were 
estimated by 1 tailed Student’s t-test. *P < 0.05. 
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Figure 4.16 Pairing by the 3’ and 5’ end of miR-503 to the 3’UTR of DDHD2 is 
necessary to repress expression. 
Shown by luciferase reporter assay activity with different sections of the miR-503 target 
site in the 3’UTR of DDHD2 deleted. The Y-axis denotes relative luciferase units from 
miR-503 transfected cells normalized to Control siRNA transfected cells. Blue bar: Intact 
3’UTRs. Red: 3’UTR with deletion of pairing to 3’ end of miR-503. Yellow: 3’UTR with 
deletion of pairing to 5’ end of miR-503. Red bars: 3’UTR with the putative miR-503 
target site entirely deleted. Error bars denote ± SD, n = 3. P-values were estimated by 1 
tailed Student’s t-test. *P < 0.05. 
 96 
 
 
Figure 4.17 miR-503 transfection decreased protein expression of DDHD2. 
DDHD2 protein expression following miR-503 transfection in fibroblasts and HeLas 
compared to Control siRNA transfection. Band intensities were quantified, normalized to 
GAPDH, and shown relative to the Control siRNA. 
4.4.5 The involvement of miR-503 in ER+ breast cancer 
 DDHD2 has previously been shown to be tumor promoting in breast cancer by 
cooperating functionally with Myc to stimulate breast cancer cell growth (120). In 
addition, DDHD2 was observed to be located in an area of high level copy number 
aberrations in breast tumors (120). Amplification of this area most frequently occurs in 
estrogen receptor positive (ER+) breast tumors (120). 
We used the MIRUMIR tool to query the prognostic value of miR-503 expression 
levels in a published data set of patients with high-risk ER+ breast cancers (93). Patients 
with high miR-503 expression had a significantly higher survival probability than 
patients with low miR-503 expression (Figure 4.18). Analysis of DDHD2 alterations 
using the cBio portal revealed that DDHD2 tends to be amplified in a variety of cancers, 
and most predominantly in breast invasive carcinoma (~12% of cases) (Figure 4.19). In 
addition, patients with copy number alterations of DDHD2 had a significantly lower 
survival probability than patients without copy number alterations of DDHD2 (Figure 
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4.20). This data suggests miR-503 plays a role in breast cancer tumorigenesis at least in 
part by targeting DDHD2. 
 
Figure 4.18 Low miR-503 expression correlates with a lower survival probability in 
ER+ breast cancer patients. 
p= 8.56e-06. Kaplan-Meier survival curves for patients with ER+ breast cancer 
expressing different levels of miR-503 were calculated using the MIRUMIR tool. 
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Figure 4.19 DDHD2 is frequently amplified in breast cancer. 
The bars are the frequency of DDHD2 copy number alterations in the different types of 
cancer indicated on the X-axis. The frequency of patients with DDHD2 amplification was 
calculated using the cBio portal. Blue: Deletion; Red: Amplification. 
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Figure 4.20 DDHD2 copy number alterations correlate with survival probability. 
Patients with copy number alterations in DDHD2 (red line) have a lower survival 
probably than those without amplifications in DDHD2 (blue line) (Logrank test p= 
0.027795). Kaplan-Meier survival curves were was calculated using the cBio portal. 
4.5 DISCUSSION 
In this study, we experimentally determined the targetome of multiple miRNAs 
that repress cell proliferation, and showed that miR-503 regulates the expression of the 
proto-oncogene DDHD2 by non-canonical targeting. We began by screening for miRNA 
involvement in primary cell proliferation, and identified miR-503, -103, and -494 as 
regulators of primary cell proliferation. We then constructed transcriptome wide target 
sets for miR-503, -103, and -494 using RIP and global gene expression profiling 
methodologies. Our analysis of the target sets revealed potentially widespread use of non-
canonical targeting for each of the miRNAs. We went on to show that miR-503 targets 
the oncogene DDHD2 non-canonically, requiring 3’ pairing of miR-503; and further 
analysis linked miR-503 to ER+ breast cancer through DDHD2. 
Recent advances in methodologies to profile the entire miRNA targetome have 
uncovered extensive mediation of RISC binding by non-canonical targeting (27-30). 
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However, the effects of non-canonical targeting on gene expression ranged from 
moderate at most, to statistically insignificant depending on the study (27, 29, 121). This 
discrepancy may be due to differences in the reliance on miRNA seed interactions to 
identify targets. In our experiments, we found evidence of extensive non-canonical 
targeting by miR-503, -103, and -494 mediating both RISC occupancy and gene 
expression. We went on to experimentally confirm that 3’ target pairing was necessary 
for miR-503 to repress DDHD2. miR-503 targeting of DDHD2 may represent an isolated 
case, but analysis of our experimentally identified transcriptome wide target set suggests 
miR-503 uses 3’ target pairing to mediate gene expression throughout its targetome. 
In addition, we showed that miR-503 acts like a tumor suppressor by non-
canonically targeting the putative oncogene DDHD2. Relatively little is known about 
DDHD2. DDHD2 was previously shown to promote tumorigenesis in breast cancer by 
cooperating functionally with Myc to enhance breast cancer cell growth (120). DDHD2 is 
located in an area that is frequently amplified in breast tumors, and most frequently in 
ER+ breast tumors (120). Our analysis showed that decreased miR-503 expression 
correlated with low patient survivability, and that DDHD2 copy number alterations were 
most frequent in invasive breast carcinoma and correlate significantly with low patient 
survivability. Taken together, these data suggest that miR-503 may function as a 
previously unknown tumor suppressor in ER+ breast cancer. 
miR-503 has been shown to act as a tumor suppressor in several cancers, and 
decreases in miR-503 expression have been reported in multiple cancer types (110, 111, 
113, 122). In addition, miR-503 has been shown to target multiple oncogenes and 
regulators of proliferation (111, 114, 122, 123). miR-503 inhibits hepatocellular 
carcinoma, glioblastoma multiforme, and non small cell lung cancer (NSCLC) 
tumorigenesis by repressing proliferation, inducing cell cycle arrest, and reducing 
metastasis (110, 111, 113, 124). Additionally, miR-503 also represses hepatocullelar 
carcinoma tumor angiogenesis by targeting the potent angiogenic factors FGF2 and 
VEGFA (113). miR-503 has also been shown to play a role in repressing endometrial 
cancer (122). Considered as a whole, these studies suggest that miR-503 operates as a 
potent tumor suppressor that regulates multiple pathways that are frequently deregulated 
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in tumorigenesis. Moderate repression of multiple key regulatory genes can have large 
phenotypic effects in concert, and miR-503 may conceivably inhibit breast cancer 
tumorigenesis by repressing multiple previously known targets in addition to DDHD2. 
In summary, we demonstrated that miR-503 represses cell proliferation, and may 
function as a tumor suppressor in ER+ cancer by utilizing non-canonical 3’ pairing to 
target the proto-oncogene DDHD2. In addition, we provide experimentally determined 
transcriptome wide target profiles of the proliferation related miRNAs miR-503, -103, 
and -494.  
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Chapter 5 Summary and Future Directions 
 In this work we: (1) Explored the function of multiple miRNAs in regulating 
proliferation; (2) Used RIP methodologies to construct transcriptome wide profiles of the 
targets of miR-191, -503, -103, and -494; (3) Discovered a miR-22 Myc regulatory 
network that links the gene networks controlling the cell cycle and interferon response (4) 
Identified multiple proto-oncogenes targeted by miR-191; and (5) Characterized the non-
canonical targeting of the proto-oncogene DDHD2 by miR-503. 
5.1 CELL TYPE SPECIFIC REGULATION 
We comprehensively demonstrated that miR-22 promotes proliferation in primary 
human fibroblasts by targeting cell cycle arrest pathways that are mediated by the tumor 
suppressor p53, and identified multiple specific inhibitors of cell cycle progression that 
are targeted by miR-22.  Other groups have also observed that miR-22 acts like a proto-
oncogene, promoting proliferation and invasion of cancer cells by inhibiting the tumor 
suppressor PTEN (39-41).  However, multiple groups have also reported that miR-22 
inhibits proliferation of several cancer cell lines (42-44).  We also showed that miR-22 up 
regulates Myc expression levels by repressing MXD4, a transcriptional repressor of Myc, 
but other groups have shown that miR-22 inhibits Myc activity by repressing Myc’s 
binding partners (42, 44). 
In addition, we demonstrated that miR-191 represses primary cell proliferation 
and targets multiple proto-oncogenes and promoters of proliferation.  miR-191 
expression significantly correlates with NSCLC survival; however, we observed varying 
and cell line specific effects on proliferation by miR-191 in NSCLC cell lines.  miR-191 
has been shown to act as an oncogene in multiple cancer types, but also has been shown 
to frequently function as a tumor suppressor in several other cancer types (83, 85, 87, 97).  
In breast cancer, Di Leva et al. elegantly demonstrated that miR-191 promotes or impairs 
tumorigenesis depending on ER-alpha receptor status (104). 
As illustrated by these examples, an individual miRNA is frequently found to 
have opposing functions depending on context.  Generally, these differences in function 
 103 
are hypothesized to depend on cell type or genetic background, and are not further 
explored.  With current advances in miRNA target identification methodologies allowing 
for significantly higher quality profiling of miRNA targets, as well as the exponential 
increases in sequencing throughput and datasets available, these cell type specific 
differences can more feasibly and should be explored.  
5.2 MIRNA TARGETING LOCATION 
 Using our experimentally determined miR-191 targetome, we showed that seed 
matches in the CDS had increased RISC occupancy and a greater effect on transcript 
levels than seed matches in the 3’ UTR.  Multiple groups have observed extensive RISC 
occupancy of the CDS; however, seed matches in the CDS having greater efficacy has 
not been previously reported (24, 26, 27, 29, 30, 95, 96).  In general seed matches in the 
CDS have been observed to have no significant effect on gene expression, but it should 
be noted that most studies examining miRNA targeting of the CDS region profiled all 
targets of the miRNAome rather than focus on a single miRNA, suggesting the signal 
may be more diffuse.  Our experiments were comprised of multiple replicates and 
isolated to one cell type and one miRNA, but this makes it difficult to draw broader 
conclusions as to the efficacy of seed matches in the CDS.  In addition, it is possible that 
the effect on gene expression is an artifact derived from highly overexpressing the 
miRNA.  As an initial step to further explore CDS targeting, CDS targeting by miR-191 
should be confirmed by luciferase reporter, and effects on protein levels examined.  More 
generally, it would be interesting to utilize cross linking methodologies, allowing for 
more robust identification of miRNA binding sites, in combination with transcriptome 
wide profiling of gene expression, to explore CDS targeting for additional miRNAs and 
in additional cell types. 
5.3 ALTERNATIVE TARGETING MECHANISMS 
 We showed that miR-503 requires pairing of its 3’ end to the 3’ UTR of DDHD2 
to effectively repress gene expression despite the presence of a 7-mer seed match.  
Complementary miRNA-target pairing with a perfect 5’ seed match and additional 
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pairing at the 3’ end has been previously reported; however, while the 3’ pairing 
enhanced target repression, it was not necessary for miRNA function.   Multiple studies 
have reported extensive non-canonical miRNA-target pairing with mismatches in the 
seed, but the effect on gene expression by non-canonical targeting was minor (24, 27, 29, 
30).  miR-503 pairing to DDHD2 differs from this type of non-canonical pairing by 
utilizing a perfect seed match, but it also differs from standard compensatory pairing 
because the 3’ pairing is necessary.  Taken together, this data raises multiple questions: 
(1) Is miR-503 DDHD2 pairing an isolated case or is miRNA-target pairing that requires 
3’ pairing in addition to a perfect seed match more widespread? (2) Do a subset of 
miRNAs utilize non-canonical targeting to regulate gene expression?  Most studies 
exploring miRNA targeting examined either the entire miRNA targetome or a single 
miRNA-target interaction, and if a minority subset of miRNAs utilize extensive non-
canonical targeting this signal may be lost when the whole targetome is considered. (3) 
Can miR-503 be confirmed to require 3’ target pairing to regulate expression of other 
genes?  And if so, what fraction of its total targets?  
5.4 MIR-503 IN BREAST CANCER 
 Our identification of DDHD2 as a direct target of miR-503 and our analysis of 
available clinical data strongly suggested that miR-503 functions as a tumor suppressor in 
ER+ breast cancer.  We showed that high miR-503 expression correlated with increased 
patient survival.  DDHD2 has been reported to function as an oncogene in ER+ breast 
cancer, and we observed that DDHD2 frequently exhibits copy number alterations in 
ER+ breast cancer and the copy number alterations correlated with decreased patient 
survival (120).  Taken together these data suggest multiple avenues of further 
exploration: (1) Exploring miR-503 regulation of proliferation in ER+ breast cancer cell 
lines; (2) Examining miR-503 point mutation and copy number alterations in ER+ breast 
cancer cohorts; (3) Identifying other miR-503 oncogenic targets in ER+ breast cancer; (4) 
Determining if miR-503 suppresses ER+ breast cancer tumorigenesis through a single 
linear pathway or if it operates through a broader network of pathways; and (5) 
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Investigating if there is a more specific genetic background in which miR-503 functions 
as a tumor suppressor. 
5.5 EXPLORING ALTERNATIVE FUNCTIONS 
 Transcriptome wide target identification for this group of miRNAs was used as a 
tool to understand the regulation of proliferation by these miRNAs.  We explored the 
pathways associated with proliferation that were regulated by miR-22, and partially for 
miR-191 and miR-503; however, we did not pursue any of the interesting proliferation 
associated targets identified for miR-494 or miR-103.  In addition, we limited our focus 
to proliferation associated genes because we were exploring a specific phenotype, but 
there may be other interesting functions that are regulated by these miRNAs.  miRNAs 
frequently regulate multiple functions and pathways, and it is likely that this group of 
miRNAs is significantly involved in mediating other important biological processes (19).  
There remains a great deal of biology available to explore through this large dataset we 
have produced of multiple miRNA targetomes. 
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Appendix 
GO Term Enrichment analysis for experimentally determined miRNA target sets. 
miR-191 
GO Term Biological Process 
 
Hyp 
 
Hyp 
Corrected 
toll-like receptor signaling pathway (BP) 6.54E-07 0.000725541 
toll-like receptor 1 signaling pathway (BP) 3.98E-06 0.000881722 
toll-like receptor 2 signaling pathway (BP) 3.98E-06 0.000881722 
toll-like receptor 4 signaling pathway (BP) 7.48E-06 0.00103675 
regulation of transcription, DNA-dependent (BP) 6.85E-06 0.00108474 
Toll signaling pathway (BP) 9.11E-06 0.0011229 
MyD88-dependent toll-like receptor signaling pathway 
(BP) 6.10E-06 0.00112737 
MyD88-independent toll-like receptor signaling 
pathway (BP) 2.51E-06 0.00139424 
protein transport (BP) 3.84E-06 0.00142073 
toll-like receptor 3 signaling pathway (BP) 2.14E-05 0.00236779 
stress-activated MAPK cascade (BP) 7.51E-05 0.00757622 
anti-apoptosis (BP) 8.87E-05 0.00819412 
gene expression (BP) 0.000144769 0.0114678 
cell division (BP) 0.000144454 0.0123231 
regulation of translation in response to stress (BP) 0.000178871 0.0132245 
mitotic cell cycle (BP) 0.000261759 0.0170759 
vesicle-mediated transport (BP) 0.000285185 0.0175705 
canonical Wnt receptor signaling pathway (BP) 0.000256932 0.0178086 
innate immune response (BP) 0.000306104 0.0178668 
cell proliferation (BP) 0.000335669 0.0186129 
gonad development (BP) 0.000375344 0.0198217 
transcription from RNA polymerase II promoter (BP) 0.000673591 0.0339551 
positive regulation of macrophage derived foam cell 
differentiation (BP) 0.000777607 0.0374942 
chromatin modification (BP) 0.000946698 0.0437453 
multicellular organismal development (BP) 0.00108807 0.0446914 
JUN phosphorylation (BP) 0.00105424 0.0449675 
regulation of DNA-dependent transcription in response 
to stress (BP) 0.00105424 0.0449675 
lipid storage (BP) 0.00117275 0.0464491 
apoptotic process (BP) 0.00123455 0.047211 
spermatogenesis (BP) 0.001287 0.0475761 
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KEGG Pathway Enrichment Hyp 
Hyp 
Corrected 
Toll-like receptor signaling pathway 0.00242287 0.0329106 
Adipocytokine signaling pathway 0.0020567 0.0304765 
Focal adhesion 0.00143282 0.023355 
Prostate cancer 0.00119769 0.0216915 
MAPK signaling pathway 0.000886753 0.0180676 
Hepatitis C 0.00044294 0.0120332 
Ribosome biogenesis in eukaryotes 0.000445001 0.0103622 
Phosphatidylinositol signaling system 7.27E-05 0.00236896 
Pathways in cancer 3.70E-05 0.00200889 
Neurotrophin signaling pathway 4.66E-05 0.00189977 
Inositol phosphate metabolism 1.09E-05 0.00089092 
Small cell lung cancer 1.94E-06 0.000315659 
 
miR-503 
GO Term Biological Process 
 
Hyp 
 
Hyp 
Corrected 
translational elongation (BP) 8.36E-05 0.0172273 
translation (BP) 0.000326803 0.0336607 
septin ring assembly (BP) 0.00245557 0.0337231 
oncosis (BP) 0.00245557 0.0337231 
sialic acid transport (BP) 0.00245557 0.0337231 
glycine decarboxylation via glycine cleavage system (BP) 0.00245557 0.0337231 
ER-associated misfolded protein catabolic process (BP) 0.00245557 0.0337231 
protein K48-linked ubiquitination (BP) 0.00264529 0.0340582 
gene expression (BP) 0.000515233 0.0353793 
posttranscriptional regulation of gene expression (BP) 0.00490517 0.0360881 
regulation of microtubule polymerization (BP) 0.00490517 0.0360881 
acetylcholine transport (BP) 0.00490517 0.0360881 
eosinophil degranulation (BP) 0.00490517 0.0360881 
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cellular response to potassium ion starvation (BP) 0.00490517 0.0360881 
rRNA export from nucleus (BP) 0.00490517 0.0360881 
regulation of translation in response to stress (BP) 0.00490517 0.0360881 
endonucleolytic cleavage to generate mature 3'-end of 
SSU-rRNA from (SSU-rRNA, 5.8S rRNA, LSU-rRNA) 
(BP) 0.00490517 0.0360881 
negative regulation of gene silencing by miRNA (BP) 0.00490517 0.0360881 
cellular protein metabolic process (BP) 0.00533524 0.0378986 
mitotic cell cycle DNA replication checkpoint (BP) 0.00734884 0.0398384 
cellular response to erythropoietin (BP) 0.00734884 0.0398384 
peptidyl-cysteine methylation (BP) 0.00734884 0.0398384 
negative regulation of GTPase activity (BP) 0.00734884 0.0398384 
minus-end-directed organelle transport along microtubule 
(BP) 0.00734884 0.0398384 
mitotic cell cycle spindle checkpoint (BP) 0.00734884 0.0398384 
arginyl-tRNA aminoacylation (BP) 0.00734884 0.0398384 
chaperone-mediated protein folding (BP) 0.00734884 0.0398384 
negative regulation of cysteine-type endopeptidase 
activity involved in apoptotic process (BP) 0.00757002 0.0399852 
endocrine pancreas development (BP) 0.00333896 0.0404603 
positive regulation of cell differentiation (BP) 0.00158771 0.0408835 
regulation of cyclin-dependent protein kinase activity 
(BP) 0.00813201 0.0418799 
endonucleolytic cleavage in ITS1 to separate SSU-rRNA 
from 5.8S rRNA and LSU-rRNA from tricistronic rRNA 
transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) (BP) 0.00978657 0.0428943 
response to purine-containing compound (BP) 0.00978657 0.0428943 
positive regulation of vesicle fusion (BP) 0.00978657 0.0428943 
antral ovarian follicle growth (BP) 0.00978657 0.0428943 
regulation of DNA-dependent transcription in response to 
stress (BP) 0.00978657 0.0428943 
cellular response to nutrient (BP) 0.00978657 0.0428943 
RNA metabolic process (BP) 0.00375194 0.0429389 
viral infectious cycle (BP) 0.0014849 0.0436986 
viral reproduction (BP) 0.00887137 0.0445732 
protein K63-linked ubiquitination (BP) 0.00133308 0.0457692 
regulation of catalytic activity (BP) 0.0067616 0.0464296 
mRNA metabolic process (BP) 0.0022566 0.046486 
cell cycle (BP) 0.00440884 0.0478011 
neutrophil degranulation (BP) 0.0122184 0.0484036 
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tubulin complex assembly (BP) 0.0122184 0.0484036 
ubiquitin-dependent SMAD protein catabolic process (BP) 0.0122184 0.0484036 
cellular response to acid (BP) 0.0122184 0.0484036 
germ cell development (BP) 0.00216066 0.0494551 
 
miR-103 
GO Term Biological Process 
 
Hyp 
 
Hyp 
Corrected 
interleukin-4-mediated signaling pathway (BP) 0.00420517 0.0455841 
production of molecular mediator involved in inflammatory 
response (BP) 0.00420517 0.0455841 
nuclear envelope disassembly (BP) 0.00420517 0.0455841 
polar body extrusion after meiotic divisions (BP) 0.00420517 0.0455841 
methionyl-tRNA aminoacylation (BP) 0.00420517 0.0455841 
mitotic prophase (BP) 0.00420517 0.0455841 
cellular amino acid catabolic process (BP) 0.00420517 0.0455841 
D-serine transport (BP) 0.00420517 0.0455841 
mannose biosynthetic process (BP) 0.00420517 0.0455841 
positive regulation of odontogenesis of dentin-containing 
tooth (BP) 0.00420517 0.0455841 
regulation of mitotic anaphase (BP) 0.00420517 0.0455841 
activation of mitotic anaphase-promoting complex activity 
(BP) 0.00420517 0.0455841 
positive regulation of DNA metabolic process (BP) 0.00630122 0.0461521 
termination of signal transduction (BP) 0.00630122 0.0461521 
negative regulation of T-helper 1 cell differentiation (BP) 0.00630122 0.0461521 
central nervous system neuron axonogenesis (BP) 0.00630122 0.0461521 
positive regulation of axon regeneration (BP) 0.00630122 0.0461521 
activation of Cdc42 GTPase activity (BP) 0.00630122 0.0461521 
embryonic skeletal limb joint morphogenesis (BP) 0.00630122 0.0461521 
heart valve morphogenesis (BP) 0.00630122 0.0461521 
spermidine biosynthetic process (BP) 0.00630122 0.0461521 
protein localization to chromatin (BP) 0.00630122 0.0461521 
ER to Golgi vesicle-mediated transport (BP) 0.00444203 0.0462996 
 
miR-494 
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GO Term Biological Process 
 
Hyp 
 
Hyp 
Corrected 
transcription from RNA polymerase II promoter (BP) 5.76E-07 0.00077091 
transcription, DNA-dependent (BP) 1.56E-06 0.00104253 
S phase of mitotic cell cycle (BP) 2.81E-06 0.00125464 
protein transport (BP) 3.84E-06 0.00128557 
response to DNA damage stimulus (BP) 9.99E-06 0.00222775 
cell death (BP) 8.98E-06 0.00240313 
regulation of transcription, DNA-dependent (BP) 1.52E-05 0.00290808 
positive regulation of I-kappaB kinase/NF-kappaB 
cascade (BP) 2.05E-05 0.00342125 
histone H4-R3 methylation (BP) 2.34E-05 0.00347463 
positive regulation of apoptotic process (BP) 3.09E-05 0.00412906 
DNA repair (BP) 3.52E-05 0.00428337 
signal transduction (BP) 6.14E-05 0.00632049 
liver development (BP) 6.67E-05 0.00637801 
neural tube closure (BP) 6.03E-05 0.00672292 
negative regulation of sequence-specific DNA binding 
transcription factor activity (BP) 8.36E-05 0.00745652 
multicellular organismal development (BP) 9.00E-05 0.00752423 
regulation of apoptotic process (BP) 0.000110389 0.00868828 
G1/S transition of mitotic cell cycle (BP) 0.000155688 0.0115728 
negative regulation of transcription from RNA 
polymerase II promoter (BP) 0.000180342 0.0120649 
apoptotic process (BP) 0.000177874 0.0125261 
RNA metabolic process (BP) 0.000201523 0.0128399 
amino acid transport (BP) 0.000212041 0.0128959 
cell migration involved in sprouting angiogenesis (BP) 0.000266785 0.0148732 
DNA damage response, signal transduction by p53 class 
mediator resulting in cell cycle arrest (BP) 0.000256932 0.0149467 
RNA splicing (BP) 0.000285622 0.0152865 
intracellular protein transport (BP) 0.00033602 0.0166516 
angiogenesis (BP) 0.000324596 0.0167042 
cell cycle arrest (BP) 0.000360897 0.0172457 
cellular nitrogen compound metabolic process (BP) 0.0003942 0.0181876 
actin polymerization or depolymerization (BP) 0.000479442 0.0213831 
regulation of smooth muscle cell migration (BP) 0.000531843 0.0215638 
negative regulation of monocyte differentiation (BP) 0.000531843 0.0215638 
negative regulation of cell division (BP) 0.000531843 0.0215638 
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JNK cascade (BP) 0.000595673 0.0227717 
transport (BP) 0.000587736 0.0231291 
response to hypoxia (BP) 0.000622661 0.0231422 
negative regulation of cysteine-type endopeptidase 
activity involved in apoptotic process (BP) 0.000711948 0.0257456 
protein homooligomerization (BP) 0.00106255 0.0330625 
peptidyl-arginine methylation (BP) 0.00105424 0.0335852 
entrainment of circadian clock by photoperiod (BP) 0.00105424 0.0335852 
regulation of proteasomal ubiquitin-dependent protein 
catabolic process (BP) 0.00105424 0.0335852 
negative regulation of transcription, DNA-dependent 
(BP) 0.00114499 0.0340443 
small GTPase mediated signal transduction (BP) 0.00112461 0.0341984 
vesicle-mediated transport (BP) 0.001199 0.0348754 
response to calcium ion (BP) 0.000994371 0.0350123 
innate immune response (BP) 0.00103562 0.0355296 
transforming growth factor beta receptor signaling 
pathway (BP) 0.00179774 0.0421996 
cellular membrane organization (BP) 0.00177641 0.0424435 
viral reproduction (BP) 0.00175717 0.0427472 
positive regulation of NF-kappaB transcription factor 
activity (BP) 0.00150707 0.0429035 
positive regulation of T-helper 1 cell differentiation (BP) 0.00174149 0.0431502 
negative regulation of leukocyte migration (BP) 0.00174149 0.0431502 
anti-apoptosis (BP) 0.00158985 0.0434126 
response to estrogen stimulus (BP) 0.0015635 0.0435825 
interspecies interaction between organisms (BP) 0.00171326 0.0440835 
mRNA processing (BP) 0.00170199 0.0446523 
2-oxoglutarate metabolic process (BP) 0.00167523 0.0448292 
neuron projection development (BP) 0.0020567 0.0466417 
nucleotide-excision repair (BP) 0.0020567 0.0466417 
positive regulation of sequence-specific DNA binding 
transcription factor activity (BP) 0.00219591 0.0489687 
 112 
References 
1. Coller, H.A., Sang, L. and Roberts, J.M. (2006) A new description of cellular 
quiescence. PLoS Biol., 4, e83. 
2. Matsumoto, A., Takeishi, S., Kanie, T., Susaki, E., Onoyama, I., Tateishi, Y., 
Nakayama, K. and Nakayama, K.I. (2011) p57 is required for quiescence and 
maintenance of adult hematopoietic stem cells. Cell Stem Cell, 9, 262–271. 
3. White, P., Brestelli, J.E., Kaestner, K.H. and Greenbaum, L.E. (2005) Identification of 
transcriptional networks during liver regeneration. J. Biol. Chem., 280, 3715–3722. 
4. Yusuf, I. and Fruman, D.A. (2003) Regulation of quiescence in lymphocytes. Trends 
Immunol., 24, 380–386. 
5. Tzachanis, D., Lafuente, E.M., Li, L. and Boussiotis, V.A. (2004) Intrinsic and 
extrinsic regulation of T lymphocyte quiescence. Leuk. Lymphoma, 45, 1959–1967. 
6. Martin, P. (1997) Wound healing--aiming for perfect skin regeneration. Science, 276, 
75–81. 
7. Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of cancer: the next generation. 
Cell, 144, 646–674. 
8. Vogelstein, B., Papadopoulos, N., Velculescu, V.E., Zhou, S., Diaz, L.A. and Kinzler, 
K.W. (2013) Cancer genome landscapes. Science, 339, 1546–1558. 
9. Chang, H.Y., Sneddon, J.B., Alizadeh, A.A., Sood, R., West, R.B., Montgomery, K., 
Chi, J.-T., van de Rijn, M., Botstein, D. and Brown, P.O. (2004) Gene expression 
signature of fibroblast serum response predicts human cancer progression: 
similarities between tumors and wounds. PLoS Biol., 2, E7. 
10. Chang, H.Y., Nuyten, D.S.A., Sneddon, J.B., Hastie, T., Tibshirani, R., Sørlie, T., 
Dai, H., He, Y.D., van't Veer, L.J., Bartelink, H., et al. (2005) Robustness, 
scalability, and integration of a wound-response gene expression signature in 
predicting breast cancer survival. Proc. Natl. Acad. Sci. U.S.A., 102, 3738–3743. 
11. Iyer, V.R., Eisen, M.B., Ross, D.T., Schuler, G., Moore, T., Lee, J.C., Trent, J.M., 
Staudt, L.M., Hudson, J.J., Boguski, M.S., et al. (1999) The transcriptional program 
in the response of human fibroblasts to serum. Science, 283, 83–87. 
12. Croce, C.M. and Calin, G.A. (2005) miRNAs, cancer, and stem cell division. Cell, 
122, 6–7. 
13. Davis, B.N. and Hata, A. (2009) Regulation of MicroRNA Biogenesis: A miRiad of 
 113 
mechanisms. Cell Commun. Signal, 7, 18. 
14. Friedman, R.C., Farh, K.K.-H., Burge, C.B. and Bartel, D.P. (2009) Most mammalian 
mRNAs are conserved targets of microRNAs. Genome Res., 19, 92–105. 
15. Lim, L.P., Lau, N.C., Garrett-Engele, P., Grimson, A., Schelter, J.M., Castle, J., 
Bartel, D.P., Linsley, P.S. and Johnson, J.M. (2005) Microarray analysis shows that 
some microRNAs downregulate large numbers of target mRNAs. Nature, 433, 769–
773. 
16. Sun, X., Jiao, X., Pestell, T.G., Fan, C., Qin, S., Mirabelli, E., Ren, H. and Pestell, 
R.G. (2013) MicroRNAs and cancer stem cells: the sword and the shield. Oncogene. 
17. Li, Y. and Kowdley, K.V. (2012) MicroRNAs in Common Human Diseases. 
Genomics Proteomics Bioinformatics, 10, 246–253. 
18. Griffiths-Jones, S., Saini, H.K., van Dongen, S. and Enright, A.J. (2008) miRBase: 
tools for microRNA genomics. Nucleic Acids Res., 36, D154–8. 
19. Mendell, J.T. and Olson, E.N. (2012) MicroRNAs in stress signaling and human 
disease. Cell, 148, 1172–1187. 
20. Ameres, S.L. and Zamore, P.D. (2013) Diversifying microRNA sequence and 
function. Nat. Rev. Mol. Cell Biol., 14, 475–488. 
21. Yang, J.-S. and Lai, E.C. (2011) Alternative miRNA biogenesis pathways and the 
interpretation of core miRNA pathway mutants. Mol. Cell, 43, 892–903. 
22. Czech, B. and Hannon, G.J. (2011) Small RNA sorting: matchmaking for 
Argonautes. Nat. Rev. Genet., 12, 19–31. 
23. Bartel, D.P. (2009) MicroRNAs: target recognition and regulatory functions. Cell, 
136, 215–233. 
24. Grimson, A., Farh, K.K.-H., Johnston, W.K., Garrett-Engele, P., Lim, L.P. and Bartel, 
D.P. (2007) MicroRNA targeting specificity in mammals: determinants beyond seed 
pairing. Mol. Cell, 27, 91–105. 
25. Guo, H., Ingolia, N.T., Weissman, J.S. and Bartel, D.P. (2010) Mammalian 
microRNAs predominantly act to decrease target mRNA levels. Nature, 466, 835–
840. 
26. Lim, L. P., Lau, N.C., Garrett-Engele, P., Grimson, A., Schelter, J.M., Castle, J., 
Bartel, D.P., Linsley, P.S. and Johnson, J.M. (2005) Microarray analysis shows that 
some microRNAs downregulate large numbers of target mRNAs. Nature, 433, 769–
773. 
 114 
27. Helwak, A., Kudla, G., Dudnakova, T. and Tollervey, D. (2013) Mapping the human 
miRNA interactome by CLASH reveals frequent noncanonical binding. Cell, 153, 
654–665. 
28. Chi, S.W., Hannon, G.J. and Darnell, R.B. (2012) An alternative mode of microRNA 
target recognition. Nat. Struct. Mol. Biol., 19, 321–327. 
29. Loeb, G.B., Khan, A.A., Canner, D., Hiatt, J.B., Shendure, J., Darnell, R.B., Leslie, 
C.S. and Rudensky, A.Y. (2012) Transcriptome-wide miR-155 Binding Map Reveals 
Widespread Noncanonical MicroRNA Targeting. Mol. Cell, 48, 760–770. 
30. Hafner, M., Landthaler, M., Burger, L., Khorshid, M., Hausser, J., Berninger, P., 
Rothballer, A., Ascano, M., Jungkamp, A.-C., Munschauer, M., et al. (2010) 
Transcriptome-wide identification of RNA-binding protein and microRNA target 
sites by PAR-CLIP. Cell, 141, 129–141. 
31. Calin, G.A., Sevignani, C., Dumitru, C.D., Hyslop, T., Noch, E., Yendamuri, S., 
Shimizu, M., Rattan, S., Bullrich, F., Negrini, M., et al. (2004) Human microRNA 
genes are frequently located at fragile sites and genomic regions involved in cancers. 
Proc. Natl. Acad. Sci. U.S.A., 101, 2999–3004. 
32. Volinia, S., Calin, G.A., Liu, C.-G., Ambs, S., Cimmino, A., Petrocca, F., Visone, R., 
Iorio, M., Roldo, C., Ferracin, M., et al. (2006) A microRNA expression signature of 
human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. U.S.A., 103, 
2257–2261. 
33. Calin, G.A., Dumitru, C.D., Shimizu, M., Bichi, R., Zupo, S., Noch, E., Aldler, H., 
Rattan, S., Keating, M., Rai, K., et al. (2002) Frequent deletions and down-regulation 
of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. 
Proc. Natl. Acad. Sci. U.S.A., 99, 15524–15529. 
34. Samantarrai, D., Dash, S., Chhetri, B. and Mallick, B. (2013) Genomic and 
epigenomic cross-talks in the regulatory landscape of miRNAs in breast cancer. Mol. 
Cancer Res., 11, 315–328. 
35. Papagiannakopoulos, T., Shapiro, A. and Kosik, K.S. (2008) MicroRNA-21 targets a 
network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res., 68, 
8164–8172. 
36. Schramedei, K., Mörbt, N., Pfeifer, G., Läuter, J., Rosolowski, M., Tomm, J.M., 
Bergen, von, M., Horn, F. and Brocke-Heidrich, K. (2011) MicroRNA-21 targets 
tumor suppressor genes ANP32A and SMARCA4. Oncogene, 30, 2975–2985. 
37. Deng, S., Calin, G.A., Croce, C.M., Coukos, G. and Zhang, L. (2008) Mechanisms of 
microRNA deregulation in human cancer. Cell Cycle, 7, 2643–2646. 
 115 
38. Kumar, M.S., Lu, J., Mercer, K.L., Golub, T.R. and Jacks, T. (2007) Impaired 
microRNA processing enhances cellular transformation and tumorigenesis. Nat. 
Genet., 39, 673–677. 
39. Bar, N. and Dikstein, R. (2010) miR-22 forms a regulatory loop in PTEN/AKT 
pathway and modulates signaling kinetics. PLoS ONE, 5, e10859. 
40. Liu, L., Jiang, Y., Zhang, H., Greenlee, A.R., Yu, R. and Yang, Q. (2010) miR-22 
functions as a micro-oncogene in transformed human bronchial epithelial cells 
induced by anti-benzo[a]pyrene-7,8-diol-9,10-epoxide. Toxicol In Vitro, 24, 1168–
1175. 
41. Poliseno, L., Salmena, L., Riccardi, L., Fornari, A., Song, M.S., Hobbs, R.M., 
Sportoletti, P., Varmeh, S., Egia, A., Fedele, G., et al. (2010) Identification of the 
miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that 
cooperates with its host gene MCM7 in transformation. Sci Signal, 3, 29. 
42. Ting, Y., Medina, D.J., Strair, R.K. and Schaar, D.G. (2010) Differentiation-
associated miR-22 represses Max expression and inhibits cell cycle progression. 
Biochem. Biophys. Res. Commun., 394, 606–611. 
43. Tsuchiya, N., Izumiya, M., Ogata-Kawata, H., Okamoto, K., Fujiwara, Y., Nakai, M., 
Okabe, A., Schetter, A.J., Bowman, E.D., Midorikawa, Y., et al. (2011) Tumor 
suppressor miR-22 determines p53-dependent cellular fate through post-
transcriptional regulation of p21. Cancer Res., 71, 4628–4639. 
44. Xiong, J., Du, Q. and Liang, Z. (2010) Tumor-suppressive microRNA-22 inhibits the 
transcription of E-box-containing c-Myc target genes by silencing c-Myc binding 
protein. Oncogene, 29, 4980–4988. 
45. Xu, D., Takeshita, F., Hino, Y., Fukunaga, S., Kudo, Y., Tamaki, A., Matsunaga, J., 
Takahashi, R.-U., Takata, T., Shimamoto, A., et al. (2011) miR-22 represses cancer 
progression by inducing cellular senescence. J. Cell Biol., 193, 409–424. 
46. Li, J., Liang, S., Yu, H., Zhang, J., Ma, D. and Lu, X. (2010) An inhibitory effect of 
miR-22 on cell migration and invasion in ovarian cancer. Gynecol. Oncol., 119, 543–
548. 
47. Kim, J., Lee, J.H. and Iyer, V.R. (2008) Global identification of Myc target genes 
reveals its direct role in mitochondrial biogenesis and its E-box usage in vivo. PLoS 
ONE, 3, e1798. 
48. Katome, T., Obata, T., Matsushima, R., Masuyama, N., Cantley, L.C., Gotoh, Y., 
Kishi, K., Shiota, H. and Ebina, Y. (2003) Use of RNA interference-mediated gene 
silencing and adenoviral overexpression to elucidate the roles of AKT/protein kinase 
B isoforms in insulin actions. J. Biol. Chem., 278, 28312–28323. 
 116 
49. Gu, J. and Iyer, V.R. (2006) PI3K signaling and miRNA expression during the 
response of quiescent human fibroblasts to distinct proliferative stimuli. Genome 
Biol., 7, R42. 
50. Dennis, G.J., Sherman, B.T., Hosack, D.A., Yang, J., Gao, W., Lane, H.C. and 
Lempicki, R.A. (2003) DAVID: Database for Annotation, Visualization, and 
Integrated Discovery. Genome Biol., 4, P3. 
51. Lee, B.-K., Bhinge, A.A. and Iyer, V.R. (2011) Wide-ranging functions of E2F4 in 
transcriptional activation and repression revealed by genome-wide analysis. Nucleic 
Acids Res., 39, 3558–3573. 
52. Hendrickson, D.G., Hogan, D.J., McCullough, H.L., Myers, J.W., Herschlag, D., 
Ferrell, J.E. and Brown, P.O. (2009) Concordant regulation of translation and mRNA 
abundance for hundreds of targets of a human microRNA. PLoS Biol., 7, e1000238. 
53. Tan, P.-H., Bay, B.-H., Yip, G., Selvarajan, S., Tan, P., Wu, J., Lee, C.-H. and Li, K.-
B. (2005) Immunohistochemical detection of Ki67 in breast cancer correlates with 
transcriptional regulation of genes related to apoptosis and cell death. Mod. Pathol., 
18, 374–381. 
54. Brizova, H., Kalinova, M., Krskova, L., Mrhalova, M. and Kodet, R. (2010) A novel 
quantitative PCR of proliferation markers (Ki-67, topoisomerase IIalpha, and TPX2): 
an immunohistochemical correlation, testing, and optimizing for mantle cell 
lymphoma. Virchows Arch., 456, 671–679. 
55. Baek, D., Villén, J., Shin, C., Camargo, F.D., Gygi, S.P. and Bartel, D.P. (2008) The 
impact of microRNAs on protein output. Nature, 455, 64–71. 
56. el-Deiry, W.S., Tokino, T., Velculescu, V.E., Levy, D.B., Parsons, R., Trent, J.M., 
Lin, D., Mercer, W.E., Kinzler, K.W. and Vogelstein, B. (1993) WAF1, a potential 
mediator of p53 tumor suppression. Cell, 75, 817–825. 
57. Ellisen, L.W., Ramsayer, K.D., Johannessen, C.M., Yang, A., Beppu, H., Minda, K., 
Oliner, J.D., McKeon, F. and Haber, D.A. (2002) REDD1, a developmentally 
regulated transcriptional target of p63 and p53, links p63 to regulation of reactive 
oxygen species. Mol. Cell, 10, 995–1005. 
58. Okamura, S., Arakawa, H., Tanaka, T., Nakanishi, H., Ng, C.C., Taya, Y., Monden, 
M. and Nakamura, Y. (2001) p53DINP1, a p53-inducible gene, regulates p53-
dependent apoptosis. Mol. Cell, 8, 85–94. 
59. Hasan, K., Cheung, C., Kaul, Z., Shah, N., Sakaushi, S., Sugimoto, K., Oka, S., Kaul, 
S.C. and Wadhwa, R. (2009) CARF Is a vital dual regulator of cellular senescence 
and apoptosis. J. Biol. Chem., 284, 1664–1672. 
 117 
60. Abbas, T. and Dutta, A. (2009) p21 in cancer: intricate networks and multiple 
activities. Nat. Rev. Cancer, 9, 400–414. 
61. Karginov, F.V., Conaco, C., Xuan, Z., Schmidt, B.H., Parker, J.S., Mandel, G. and 
Hannon, G.J. (2007) A biochemical approach to identifying microRNA targets. Proc. 
Natl. Acad. Sci. U.S.A., 104, 19291–19296. 
62. Miranda, K.C., Huynh, T., Tay, Y., Ang, Y.S., Tam, W.L., Thomson, A.M., Lim, B. 
and Rigoutsos, I. (2006) A pattern-based method for the identification of MicroRNA 
binding sites and their corresponding heteroduplexes. Cell, 126, 1203–1217. 
63. Schoenemeyer, A., Barnes, B.J., Mancl, M.E., Latz, E., Goutagny, N., Pitha, P.M., 
Fitzgerald, K.A. and Golenbock, D.T. (2005) The interferon regulatory factor, IRF5, 
is a central mediator of toll-like receptor 7 signaling. J. Biol. Chem., 280, 17005–
17012. 
64. Takaoka, A., Yanai, H., Kondo, S., Duncan, G., Negishi, H., Mizutani, T., Kano, S., 
Honda, K., Ohba, Y., Mak, T.W., et al. (2005) Integral role of IRF-5 in the gene 
induction programme activated by Toll-like receptors. Nature, 434, 243–249. 
65. Bianchi, M.E. and Manfredi, A.A. (2007) High-mobility group box 1 (HMGB1) 
protein at the crossroads between innate and adaptive immunity. Immunol. Rev., 220, 
35–46. 
66. Yanai, H., Ban, T., Wang, Z., Choi, M.K., Kawamura, T., Negishi, H., Nakasato, M., 
Lu, Y., Hangai, S., Koshiba, R., et al. (2009) HMGB proteins function as universal 
sentinels for nucleic-acid-mediated innate immune responses. Nature, 462, 99–103. 
67. Yoneyama, M., Kikuchi, M., Natsukawa, T., Shinobu, N., Imaizumi, T., Miyagishi, 
M., Taira, K., Akira, S. and Fujita, T. (2004) The RNA helicase RIG-I has an 
essential function in double-stranded RNA-induced innate antiviral responses. Nat. 
Immunol., 5, 730–737. 
68. Pandey, A.K., Yang, Y., Jiang, Z., Fortune, S.M., Coulombe, F., Behr, M.A., 
Fitzgerald, K.A., Sassetti, C.M. and Kelliher, M.A. (2009) NOD2, RIP2 and IRF5 
play a critical role in the type I interferon response to Mycobacterium tuberculosis. 
PLoS Pathog., 5, e1000500. 
69. Liu, H., Adler, A.S., Segal, E. and Chang, H.Y. (2007) A transcriptional program 
mediating entry into cellular quiescence. PLoS Genet., 3, e91. 
70. Fensterl, V. and Sen, G.C. (2009) Interferons and viral infections. Biofactors, 35, 14–
20. 
71. O'Donnell, K.A., Wentzel, E.A., Zeller, K.I., Dang, C.V. and Mendell, J.T. (2005) c-
Myc-regulated microRNAs modulate E2F1 expression. Nature, 435, 839–843. 
 118 
72. Lee, B.-K., Bhinge, A.A., Battenhouse, A., McDaniell, R.M., Liu, Z., Song, L., Ni, 
Y., Birney, E., Lieb, J.D., Furey, T.S., et al. (2012) Cell-type specific and 
combinatorial usage of diverse transcription factors revealed by genome-wide 
binding studies in multiple human cells. Genome Res., 22, 9–24. 
73. Marson, A., Levine, S.S., Cole, M.F., Frampton, G.M., Brambrink, T., Johnstone, S., 
Guenther, M.G., Johnston, W.K., Wernig, M., Newman, J., et al. (2008) Connecting 
microRNA genes to the core transcriptional regulatory circuitry of embryonic stem 
cells. Cell, 134, 521–533. 
74. Mao, D.Y., Watson, J.D., Yan, P.S., Barsyte-Lovejoy, D., Khosravi, F., Wong, W.W., 
Farnham, P.J., Huang, T.H. and Penn, L.Z. (2003) Analysis of Myc bound loci 
identified by CpG island arrays shows that Max is essential for Myc-dependent 
repression. Curr. Biol., 13, 882–886. 
75. Kime, L. and Wright, S.C. (2003) Mad4 is regulated by a transcriptional repressor 
complex that contains Miz-1 and c-Myc. Biochem. J., 370, 291–298. 
76. Marcotte, R., Chen, J.M., Huard, S. and Wang, E. (2005) c-Myc creates an activation 
loop by transcriptionally repressing its own functional inhibitor, hMad4, in young 
fibroblasts, a loop lost in replicatively senescent fibroblasts. J. Cell. Biochem., 96, 
1071–1085. 
77. Taylor-Papadimitriou, J., Balkwill, F., Ebsworth, N. and Rozengurt, E. (1985) 
Antiviral and antiproliferative effects of interferons in quiescent fibroblasts are 
dissociable. Virology, 147, 405–412. 
78. Barnes, B.J., Kellum, M.J., Pinder, K.E., Frisancho, J.A. and Pitha, P.M. (2003) 
Interferon regulatory factor 5, a novel mediator of cell cycle arrest and cell death. 
Cancer Res., 63, 6424–6431. 
79. Mori, T., Anazawa, Y., Iiizumi, M., Fukuda, S., Nakamura, Y. and Arakawa, H. 
(2002) Identification of the interferon regulatory factor 5 gene (IRF-5) as a direct 
target for p53. Oncogene, 21, 2914–2918. 
80. Li, Q., Tang, L., Roberts, P. C., Kraniak, J.M., Fridman, A.L., Kulaeva, O.I., Tehrani, 
O.S. and Tainsky, M.A. (2008) Interferon regulatory factors IRF5 and IRF7 inhibit 
growth and induce senescence in immortal Li-Fraumeni fibroblasts. Mol. Cancer 
Res., 6, 770–784. 
81. Ho, A. and Dowdy, S.F. (2002) Regulation of G(1) cell-cycle progression by 
oncogenes and tumor suppressor genes. Curr Opin Genet Dev, 12, 47–52. 
82. Sachdeva, M., Zhu, S., Wu, F., Wu, H., Walia, V., Kumar, S., Elble, R., Watabe, K. 
and Mo, Y.Y. (2009) p53 represses c-Myc through induction of the tumor suppressor 
miR-145. Proc. Natl. Acad. Sci. U.S.A., 106, 3207–3212. 
 119 
83. Elyakim, E., Sitbon, E., Faerman, A., Tabak, S., Montia, E., Belanis, L., Dov, A., 
Marcusson, E.G., Bennett, C.F., Chajut, A., et al. (2010) hsa-miR-191 is a candidate 
oncogene target for hepatocellular carcinoma therapy. Cancer Res., 70, 8077–8087. 
84. Shi, X., Su, S., Long, J., Mei, B. and Chen, Y. (2011) MicroRNA-191 targets N-
deacetylase/N-sulfotransferase 1 and promotes cell growth in human gastric 
carcinoma cell line MGC803. Acta Biochim. Biophys. Sin. (Shanghai), 43, 849–856. 
85. Qin, S., Zhu, Y., Ai, F., Li, Y., Bai, B., Yao, W. and Dong, L. (2013) MicroRNA-191 
correlates with poor prognosis of colorectal carcinoma and plays multiple roles by 
targeting tissue inhibitor of metalloprotease 3. Neoplasma, 10.4149/neo_2014_005. 
86. He, Y., Cui, Y., Wang, W., Gu, J., Guo, S., Ma, K. and Luo, X. (2011) 
Hypomethylation of the hsa-miR-191 locus causes high expression of hsa-mir-191 
and promotes the epithelial-to-mesenchymal transition in hepatocellular carcinoma. 
Neoplasia, 13, 841–853. 
87. Nagpal, N., Ahmad, H.M., Molparia, B. and Kulshreshtha, R. (2013) MicroRNA-191, 
an estrogen-responsive microRNA, functions as an oncogenic regulator in human 
breast cancer. Carcinogenesis, 34, 1889–1899. 
88. Lena, A.M., Mancini, M., Rivetti di Val Cervo, P., Saintigny, G., Mahé, C., Melino, 
G. and Candi, E. (2012) MicroRNA-191 triggers keratinocytes senescence by 
SATB1 and CDK6 downregulation. Biochem. Biophys. Res. Commun., 423, 509–
514. 
89. Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R. and Salzberg, S.L. (2013) 
TopHat2: accurate alignment of transcriptomes in the presence of insertions, 
deletions and gene fusions. Genome Biol., 14, R36. 
90. Tabas-Madrid, D., Nogales-Cadenas, R. and Pascual-Montano, A. (2012) 
GeneCodis3: a non-redundant and modular enrichment analysis tool for functional 
genomics. Nucleic Acids Res., 40, W478–83. 
91. Nogales-Cadenas, R., Carmona-Saez, P., Vazquez, M., Vicente, C., Yang, X., Tirado, 
F., Carazo, J.M. and Pascual-Montano, A. (2009) GeneCodis: interpreting gene lists 
through enrichment analysis and integration of diverse biological information. 
Nucleic Acids Res., 37, W317–22. 
92. Carmona-Saez, P., Chagoyen, M., Tirado, F., Carazo, J.M. and Pascual-Montano, A. 
(2007) GENECODIS: a web-based tool for finding significant concurrent annotations 
in gene lists. Genome Biol., 8, R3. 
93. Antonov, A.V., Knight, R.A., Melino, G., Barlev, N.A. and Tsvetkov, P.O. (2013) 
MIRUMIR: an online tool to test microRNAs as biomarkers to predict survival in 
cancer using multiple clinical data sets. Cell Death Differ, 20, 367. 
 120 
94. He, L., He, X., Lim, L.P., de Stanchina, E., Xuan, Z., Liang, Y., Xue, W., Zender, L., 
Magnus, J., Ridzon, D., et al. (2007) A microRNA component of the p53 tumour 
suppressor network. Nature, 447, 1130–1134. 
95. Gottwein, E., Corcoran, D.L., Mukherjee, N., Skalsky, R.L., Hafner, M., Nusbaum, 
J.D., Shamulailatpam, P., Love, C.L., Dave, S.S., Tuschl, T., et al. (2011) Viral 
microRNA targetome of KSHV-infected primary effusion lymphoma cell lines. Cell 
Host Microbe, 10, 515–526. 
96. Leung, A.K.L., Young, A.G., Bhutkar, A., Zheng, G.X., Bosson, A.D., Nielsen, C.B. 
and Sharp, P.A. (2011) Genome-wide identification of Ago2 binding sites from 
mouse embryonic stem cells with and without mature microRNAs. Nat. Struct. Mol. 
Biol., 18, 237–244. 
97. Colamaio, M., Borbone, E., Russo, L., Bianco, M., Federico, A., Califano, D., 
Chiappetta, G., Pallante, P., Troncone, G., Battista, S., et al. (2011) miR-191 Down-
Regulation Plays a Role in Thyroid Follicular Tumors through CDK6 Targeting. J 
Clin Endocrinol Metab, 96, E1915–24. 
98. Patnaik, S.K., Kannisto, E. and Yendamuri, S. (2010) Overexpression of microRNA 
miR-30a or miR-191 in A549 lung cancer or BEAS-2B normal lung cell lines does 
not alter phenotype. PLoS ONE, 5, e9219. 
99. Romano, G. and Giordano, A. (2008) Role of the cyclin-dependent kinase 9-related 
pathway in mammalian gene expression and human diseases. Cell Cycle, 7, 3664–
3668. 
100. Fan, X., Mikolaenko, I., Elhassan, I., Ni, X., Wang, Y., Ball, D., Brat, D.J., Perry, A. 
and Eberhart, C.G. (2004) Notch1 and notch2 have opposite effects on embryonal 
brain tumor growth. Cancer Res., 64, 7787–7793. 
101. Koch, U. and Radtke, F. (2007) Notch and cancer: a double-edged sword. Cell. Mol. 
Life Sci., 64, 2746–2762. 
102. Smith, J.A., Poteet-Smith, C.E., Xu, Y., Errington, T.M., Hecht, S.M. and Lannigan, 
D.A. (2005) Identification of the first specific inhibitor of p90 ribosomal S6 kinase 
(RSK) reveals an unexpected role for RSK in cancer cell proliferation. Cancer Res., 
65, 1027–1034. 
103. Kang, S., Dong, S., Gu, T.-L., Guo, A., Cohen, M.S., Lonial, S., Khoury, H.J., 
Fabbro, D., Gilliland, D.G., Bergsagel, P.L., et al. (2007) FGFR3 activates RSK2 to 
mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and 
activation of the MEK/ERK pathway. Cancer Cell, 12, 201–214. 
104. Di Leva, G., Piovan, C., Gasparini, P., Ngankeu, A., Taccioli, C., Briskin, D., 
Cheung, D.G., Bolon, B., Anderlucci, L., Alder, H., et al. (2013) Estrogen mediated-
 121 
activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells 
depending on estrogen receptor status. PLoS Genet., 9, e1003311. 
105. Lee, D. and Shin, C. (2012) MicroRNA-target interactions: new insights from 
genome-wide approaches. Ann. N. Y. Acad. Sci., 1271, 118–128. 
106. Chen, H.-Y., Lin, Y.-M., Chung, H.-C., Lang, Y.-D., Lin, C.-J., Huang, J., Wang, 
W.-C., Lin, F.-M., Chen, Z., Huang, H.-D., et al. (2012) miR-103/107 promote 
metastasis of colorectal cancer by targeting the metastasis suppressors DAPK and 
KLF4. Cancer Res., 72, 3631–3641. 
107. Lim, L., Balakrishnan, A., Huskey, N., Jones, K.D., Jodari, M., Ng, R., Song, G., 
Riordan, J., Anderton, B., Cheung, S.-T., et al. (2013) MiR-494 within an oncogenic 
MicroRNA megacluster regulates G1/S transition in liver tumorigenesis through 
suppression of MCC. Hepatology, 59, 202–215. 
108. Romano, G., Acunzo, M., Garofalo, M., Di Leva, G., Cascione, L., Zanca, C., 
Bolon, B., Condorelli, G. and Croce, C.M. (2012) MiR-494 is regulated by ERK1/2 
and modulates TRAIL-induced apoptosis in non-small-cell lung cancer through BIM 
down-regulation. Proc. Natl. Acad. Sci. U.S.A., 109, 16570–16575. 
109. Yamanaka, S., Campbell, N.R., An, F., Kuo, S.C., Potter, J.J., Mezey, E., Maitra, A. 
and Selaru, F.M. (2012) Coordinated effects of microRNA-494 induce G₂/M arrest in 
human cholangiocarcinoma. Cell Cycle, 11, 2729–2738. 
110. Zhang, Y., Chen, X., Lian, H., Liu, J., Zhou, B., Han, S., Peng, B., Yin, J., Liu, W. 
and He, X. (2014) MicroRNA-503 acts as a tumor suppressor in glioblastoma for 
multiple antitumor effects by targeting IGF-1R. Oncol. Rep., 31, 1445–1452. 
111. Yang, Y., Liu, L., Zhang, Y., Guan, H., Wu, J., Zhu, X., Yuan, J. and Li, M. (2014) 
MiR-503 targets PI3K p85 and IKK-β and suppresses progression of non-small cell 
lung cancer. Int. J. Cancer, 10.1002/ijc.28799. 
112. Li, N., Zhang, F., Li, S. and Zhou, S. (2014) Epigenetic silencing of MicroRNA-503 
regulates FANCA expression in non-small cell lung cancer cell. Biochem. Biophys. 
Res. Commun., 444, 611–616. 
113. Zhou, B., Ma, R., Si, W., Li, S., Xu, Y., Tu, X. and Wang, Q. (2013) MicroRNA-
503 targets FGF2 and VEGFA and inhibits tumor angiogenesis and growth. Cancer 
Lett., 333, 159–169. 
114. Xiao, F., Zhang, W., Chen, L., Chen, F., Xie, H., Xing, C., Yu, X., Ding, S., Chen, 
K., Guo, H., et al. (2013) MicroRNA-503 inhibits the G1/S transition by 
downregulating cyclin D3 and E2F3 in hepatocellular carcinoma. J Transl Med, 11, 
195. 
 122 
115. Cerami, E., Gao, J., Dogrusoz, U., Gross, B.E., Sumer, S.O., Aksoy, B.A., Jacobsen, 
A., Byrne, C.J., Heuer, M.L., Larsson, E., et al. (2012) The cBio cancer genomics 
portal: an open platform for exploring multidimensional cancer genomics data. 
Cancer Discov, 2, 401–404. 
116. Polioudakis, D., Bhinge, A.A., Killion, P.J., Lee, B.-K., Abell, N.S. and Iyer, V.R. 
(2013) A Myc-microRNA network promotes exit from quiescence by suppressing the 
interferon response and cell-cycle arrest genes. Nucleic Acids Res., 41, 2239–2254. 
117. Bracken, C.P., Gregory, P.A., Kolesnikoff, N., Bert, A.G., Wang, J., Shannon, M.F. 
and Goodall, G.J. (2008) A double-negative feedback loop between ZEB1-SIP1 and 
the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res., 
68, 7846–7854. 
118. Johnston, R.J., Chang, S., Etchberger, J.F., Ortiz, C.O. and Hobert, O. (2005) 
MicroRNAs acting in a double-negative feedback loop to control a neuronal cell fate 
decision. Proc. Natl. Acad. Sci. U.S.A., 102, 12449–12454. 
119. Nelson, P.T., Wang, W.-X., Mao, G., Wilfred, B.R., Xie, K., Jennings, M.H., Gao, 
Z. and Wang, X. (2011) Specific sequence determinants of miR-15/107 microRNA 
gene group targets. Nucleic Acids Res., 39, 8163–8172. 
120. Kwek, S.S., Roy, R., Zhou, H., Climent, J., Martinez-Climent, J.A., Fridlyand, J. 
and Albertson, D.G. (2009) Co-amplified genes at 8p12 and 11q13 in breast tumors 
cooperate with two major pathways in oncogenesis. Oncogene, 28, 1892–1903. 
121. Hafner, M., Landthaler, M., Burger, L., Khorshid, M., Hausser, J., Berninger, P., 
Rothballer, A., Ascano, M., Jungkamp, A.-C., Munschauer, M., et al. (2010) PAR-
CliP--a method to identify transcriptome-wide the binding sites of RNA binding 
proteins. J Vis Exp. 
122. Xu, Y.-Y., Wu, H.-J., Ma, H.-D., Xu, L.-P., Huo, Y. and Yin, L.-R. (2013) 
MicroRNA-503 suppresses proliferation and cell cycle progression of endometrioid 
ndometrial cancer via negatively regulating cyclin D1. FEBS J., 280, 3768–3779. 
123. Forrest, A.R.R., Kanamori-Katayama, M., Tomaru, Y., Lassmann, T., Ninomiya, N., 
Takahashi, Y., de Hoon, M.J.L., Kubosaki, A., Kaiho, A., Suzuki, M., et al. (2010) 
Induction of microRNAs, mir-155, mir-222, mir-424 and mir-503, promotes 
monocytic differentiation through combinatorial regulation. Leukemia, 24, 460–466. 
124. Zhou, J. and Wang, W. (2011) Analysis of microRNA expression profiling identifies 
microRNA-503 regulates metastatic function in hepatocellular cancer cell. J Surg 
Oncol, 104, 278–283. 
